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ABSTRACT

Background: Particularly important to the mechanical performance of native
arterial blood vessels is elastin, an extracellular matrix (ECM) protein deposited
by VSMCs in the form of elastic fibers, arranged in concentric lamellae in the
media of the vessel wall. In addition to serving as major structural elements of
arterial walls, providing extensibility and elastic recoil, elastic fibers also influence
vascular cell behaviors. For these reasons tissue engineers are attempting to
exploit elastic fiber biology to enhance vascular graft design and patency.
Therefore, developing a greater understanding of the molecular mechanisms of
elastogenesis may offer opportunities to control elastogenesis in tissue
biofabrication.

Approach: To discover genes critical for elastogenesis we performed analysis of
gene expression profiles associated with elastogenesis occurring 1) during lung
and aorta development, 2) in the lung and skin in response to injury, and 3) in
vascular smooth muscle cells (VSMCs) stimulated to produce elastic fibers.
On the resulting convergent gene set we employed Promoter Analysis and
Interaction Network Toolset (PAINT) to identify transcription factor binding
regions. We also mapped binding sites for microRNA (miRNA) within the
convergent gene set. Subsequent screening for potential regulators of
elastogenesis were performed using pharmacological agonists and antagonists
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along with plasmid vector transfection to augment expression. Differences in
elastin transcription were measured by quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) and by anti-elastin immunostaining in the
development of a novel elastin ELISA. A 3D proof of concept tissue culture
model containing fibroblasts and macroporous gelatin microcarrier beads was
also established and immunostained for elastin.

Results: Our transcriptomic studies revealed a set of genes differentially
regulated in all five models of elastogenesis tested. Aside from genes that have
previously been established to act in the elastogenesis process there are >50
genes that have not been implicated in elastogenesis. Moreover, promoter
analysis of clusters of genes from the 63-gene set having a similar pattern of
regulation

during

developmental

elastogenesis

revealed

two

potential

elastogenesis regulatory network of TFs. We hypothesize that these sets of
genes contain novel positive and negative effectors of elastogenesis. Effects of
agonists, antagonists, and expression vectors of these genes on elastin
expression were quantified in cultured fibroblasts to identify agents that can be
employed to accelerate elastogenesis during tissue biofabrication.

Conclusions: The findings highlight a group of genes whose expression is
differentially expressed in multiple models of elastin formation and many not
previously associated with elastogenesis and thus may represent novel
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components of elastogenesis. Transcriptional regulatory network analysis
revealed potential transcription factor regulators of elastogenesis. Candidate
genes and transcription factors were regulated through agonist and antagonist
treatment and transfection of plasmid expression vectors in order to augment
elastogenesis in vascular tissue biofabrication.
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CHAPTER ONE
INTRODUCTION TO VASCULAR TISSUE ENGINEERING
1.1 Role of elastin fibers in tissue
Particularly important to the mechanical performance of tissues is elastin, an
extracellular matrix (ECM) protein deposited by vascular smooth muscle cells
(VSMCs) in the form of elastic fibers. Within blood vessels, especially large
elastic vessels, elastic fibers constitute a major part of the ECM (30-57% w/w in
the aorta) arranged in concentric lamellae in the media of the vessel wall (3). In
addition to serving as major structural elements of arterial walls, providing
extensibility and elastic recoil, elastic fibers also influence vascular cell behaviors
such as biochemical signaling pathways. Disruption of elastic fibers can initiate
and progressively lead to the pathology of life threatening complications such as
atherosclerosis, aneurysm and vasospasms (4, 5).
The mechanism of elastogenesis encompasses the transcription of the elastin
gene, the translation of the elastic fiber precursor monomer tropoelastin,
migration to the plasma membrane, binding to the elastin receptor, self-assembly
and cross-linking of tropoelastin by lysyl oxidase, deposition onto a microfibrillar
scaffold, and finally, elongation into a mature elastic fiber (6, 7). A deficiency in
any step may result in impaired, inhibited, or completely disrupted elastogenesis.
Some (ECM) proteins are critical to the formation of functional elastic fibers as
evidenced in genetically deficient mouse models. For example, fibulin-5 deficient
mice are characterized by disorganized elastic fibers, a tortuous aorta with loss
of compliance, severe emphysema, and loose skin (cutis laxa) (8, 9).
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Tropoelastin in these mice is synthesized but not assembled properly as
evidenced by accumulation of fragmented elastin without an increase of elastase
activity (8, 9).
Because elastin is crucial to maintaining the native structural configuration (10,
11) and regulating signaling pathways (12), failure to regenerate a healthy elastin
matrix in response to damage during disease (e.g., inflammation-mediated
elastin degradation in atherosclerosis) can severely compromise elastic tissue
homeostasis (13, 14). A major concern in the construction of tissue engineered
elastin-rich tissue is the ability to regulate cell behavior and encourage the
regeneration of elastin fibers.
Tissue engineers are attempting to exploit elastic fiber biology to enhance
vascular graft design and patency, however overcoming the deficient quality of
elastic fibers synthesized in vitro poses a challenge due to the ill-defined
mechanism and insufficient knowledge of regulatory genes. Therefore, the goal
of the study is to identify gene regulators of elastogenesis that may offer
opportunities to control elastogenesis in tissue biofabrication.

1.2 Clinical problems related to elastin and significance
Human disease and elastin. DNA deletions and mutations in the elastin gene
are associated with heritable diseases of the connective tissue (14-20).
Supravalvular aortic stenosis (SVAS) and Williams-Beuren Syndrome are
characterized by an elastin gene mutation and narrowing of the arterial tree and
increased elastinolytic activity (14-16). Another mutation of the elastin gene
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results in cutis laxa with clinical effects of inelastic skin associated with severe
aortic disease and pulmonary emphysema(17, 18). Deletions in genes
comprising the microfibrillar scaffold, such as fibrillin-1 result in Marfan's
Syndrome with a phenotype of vascular disease, including aortic aneurysms and
dissections (19, 20).

Biomechanical significance of defective elastin formation. The biological process
of aging and certain diseases is characterized by a loss of tissue elasticity
increasing the investigative efforts of biomaterials based on elastin for their
application in tissue engineering. Challenges to elastin tissue engineering revolve
around adequately controlling the process of elastin assembly into elastic fibers
or organized layers of elastic lamellae. An organized ECM containing elastic
fibers has superior mechanical structure and cellular signaling advantages over
amorphous deposits of elastin typically synthesized in vitro. To address this
impediment, we have employed DNA microarray transcriptomic profiling identify
genes that are similarly regulated in a number of systems displaying increased
expression of tropoelastin and increased formation of elastic fibers. The
proposed research will contribute to a greater understanding of the molecular
mechanisms of elastogenesis through identification and characterization of
genes regulated in multiple experimental models of elastogenesis, which have
not been previously identified. This understanding is expected to reveal new
opportunities to induce cells to produce a functional elastin architecture in
engineered vascular constructs. Ultimately, we expect this project to help
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elucidate the mechanisms necessary for adequate control of elastogenesis in
human vascular cells with clinical applications for repair and salvage of human
vasculature.

1.3 Project rationale and objectives
The underlying mechanisms of elastogenesis remain largely ill-defined.
Elastogenesis encompasses the biosynthesis of tropoelastin (TE), the elastic
fiber precursor monomer, translocation of TE to the plasma membrane, TE
binding to the elastin receptor, self-assembly and cross-linking of TE by lysyl
oxidase, deposition of crosslinked TE onto a microfibrillar scaffold, and through
iteration of this process, elongation into a mature elastic fiber (6, 7). A deficiency
in any step may result in impaired or disorganized elastogenesis. Given that the
mechanical structure and cellular signaling in elastin-containing tissues are
dependent on elastic fibers, fabricated elastic constructs must be engineered to
either have synthetic elastin-like components or elastin components produced by
cellular constituents of the constructs.

1.4 Specific aims and hypotheses
Elastic fibers are critical for the function of multiple tissues including blood
vessels, skin, lung, and auricular cartilage, periodontal ligaments and other
connective tissue (21-24). An elastic fiber’s structure is comprised of a core of
amorphous tropoelastin surrounded by a microfibrillar scaffold, which contains
numerous proteins such as fibrillin, microfibrillar-associated glycoproteins,
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fibulins, and others (25). The elastic core imparts the ability for a tissue to expand
in response to a force with minimal resistance and then recoil, or return to its
original shape (26, 27). Many applications of tissue engineering require the
property of elastic recoil to repair or replace damaged and diseased tissues (i.e.,
arterial grafts, skin grafts).
The overarching goal of this application was met by identifying regulators of
elastogenesis, which will advance an approach to regenerative medicine
involving accelerated production of elastic fibers. A number of studies point to the
severe quantitative and qualitative deficiencies in the process of elastogenesis
exhibited by cultured cells (28, 29). These deficiencies create an impediment to
the engineering of tissues requiring functional elastin architecture. Through
analysis of gene expression profiles associated with normal elastogenesis
occurring during 1) mouse lung and aorta development, 2) elastogenesis in lung
and skin in response to injury, and 3) in vascular smooth muscle cells (VSMCs)
stimulated to produce elastin fibers, we will identify genes that appear to
represent new players in the process of elastogenesis. We will also work toward
development of a novel in vitro assay to quantify incorporation of elastin into the
ECM of fibroblast monolayers, which we intend to use to further screen agents
that modulate the activities of the putative elastogenic genes identified by our
transcriptomic analysis. As a result of these studies, we expect that new
elastogenesis related genes will be defined that offer new opportunities to
regulate elastogenesis in elastic tissue biofabrication.
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Based on these findings we hypothesize that expression profiling analysis
can be used to identify modulatory genes of tropoelastin synthesis and elastic
fiber assembly (elastogenesis) that have not been previously associated with the
process. Experimentation outlined in this proposal will test this hypothesis by
determining whether candidate genes regulate tropoelastin expression and
elastic fiber assembly. These objectives will be reached through the following two
interrelated specific aims:

Aim 1: Use DNA microarray based transcriptomic profiling to identify genes that
are similarly regulated in processes in which elastogenesis is a key component.

Rationale and hypothesis:
A number of studies point to severe quantitative and qualitative
deficiencies in the process of elastogenesis mediated by cultured cells(28).
These deficiencies are an impediment to cell-based bioengineering of blood
vessels requiring functional elastin architecture. DNA microarray expression data
has been performed on in vivo developing elastin-rich tissues including the lung
(W Scott Argraves, MUSC, Charleston, SC) and aorta (Robert Mecham,
Washington University School of Medicine, St. Louis, MO) and additionally
unpublished in vitro DNA microarray expression data of vascular smooth muscle
cells (VSMCs) induced to synthesize elastin (WS Argraves and TN Wight,
Benaroya Institute at Virginia Mason, Seattle, WA). Other expression profiling
studies of in vivo wound healing occurring in elastin-rich tissues have already
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been performed and the data uploaded to the NCBI Data GeoSets(30, 31). In
light of the current caveats in synthesizing elastic fibers in vitro, a convergent
analysis of DNA microarray expression profiling data in processes in which
elastogenic is a key component (in vivo studies of nascent elastic fiber formation,
in vivo regeneration of injured elastic fibers, and in vitro VSMCs induced to
synthesize elastin) will elucidate genes regulated during elastogenesis that can
be employed in elastic tissue engineering. The set of significantly regulated
genes should include genes reported to be directly or indirectly involved with
elastogenesis in addition to other genes not yet reported to be involved.

Approach: To discover genes critical for elastogenesis we will define a range of
processes in which elastogenesis is a key component. We will conduct
experiments to collect microarray data and gather publicly available microarray
data to encompass multiple types of elastogenesis in different elastin-containing
tissues: 1) development of native elastic fibers in lung and aorta, 2) regeneration
of elastin in the wound healing response in the lung and skin, and 3) in cultured
vascular smooth muscle cells stimulated to produce elastic fibers. We will
analyze each data set individually to determine differentially expressed genes
specific to each process and then converge individual datasets to discover
regulated genes common to all elastogenic processes. From this study we will
identify a set of consistently regulated genes common to five different microarray
datasets in which elastogenesis is a key component which we will define as the
“elastogenic gene set.”
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Aim 2: Determine if candidate genes are modulators of tropoelastin expression
in an in vitro culture model.

Rationale and hypothesis: Previous transcriptomic studies have revealed
genes critical to elastic fiber formation that we anticipate to be consistently
regulated in multiple elastogenic processes. Aside from genes previously
established to act in elastogenesis, we expect to discover genes that have not
been implicated in elastogenesis. We hypothesize that this convergent set of
genes will contain positive and negative effectors of elastogenesis. Genes
regulated during the formation of elastic fibers may play a critical role in
elastogenesis, however it is possible that a regulated gene may not be essential
to the process. It is also possible that even with a low false discovery rate of
comparative transcriptomic analysis, a gene may be identified incorrectly as
being regulated during elastogenesis. It is necessary to determine whether
tropoelastin expression and elastic fiber assembly processes will be disrupted in
the case a gene is not expressed. Through the use of transcription factor
agonists/antagonists and plasmid expression vectors we will selectively
augment/inhibit expression of upregulated genes and assess the resulting effects
of elastin expression.

Approach: To discover genes critical for elastogenesis we will categorize genes
into groups through coordinately regulated functional analysis and transcription
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factor analysis as well as identify individual genes for experimental testing.
Characterization of elastic fibers from multiple processes reveals higher
organization and mechanical strength in the developmental process compared to
wound healing and in vitro formation of elastic fibers (32-34). We will refer to the
native development of elastic fibers as the gold standard and place emphasis the
expression patterns of the “elastogenic gene set.” We will categorize genes into
groups of potential enhancers and potential inhibitors of elastogenesis based on
expression patterns similar or inverse to the expression pattern of the elastin
gene in processes containing native development of elastic fibers. Enhancers of
elastogenesis will be defined following the assumption of a similar expression
pattern as elastin: at highest levels during periods of peak elastin expression
(i.e., 4-21 days postnatal (d) in the developing aorta and 10-14 d in the
developing lung) and expressed at lowest levels during minimum elastin
expression. Conversely, it is reasonable to speculate that inhibitors of
elastogenesis might display an inverse relationship to elastin: relatively low
expression during peak periods of elastin expression (i.e., 4-21 d in the aorta and
10-14 d in the developing lung) and high levels of expression during the period in
which elastogenesis subsides (i.e., >60 d postnatal in the aorta). Within the
dataset there are 20 potential enhancers of elastogenesis and 39 potential
inhibitors of elastogenesis.
Another consideration in the prioritization of genes for testing is the
availability of agonists and antagonists for each gene. Cursory evaluations reveal
that for most of the genes there are commercially available agonists and

24

antagonists and purified gene products. Furthermore, siRNAs can readily be
employed to suppress the expression of candidate genes.
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CHAPTER TWO
AN OVERVIEW OF ELASTOGENESIS
The term elastogenesis is first used in a 1964 study using electron light
microscopy to compare the aortae from fetuses, newborns, and adult. Haust et
al. clearly described a low density elastic matrix surrounded by a higher density
elastic membrane, surrounded further by arranged filaments. These “elastic
units”

originated

membrane

of

at

the

SMCs

basement

where

they

aggregate and fuse to form larger
elements of elastic tissue, a process
defined as elastogenesis.
It is now known that an elastic
fiber is composed of a crosslinked
tropoelastin core surrounded by a
sheath of microfibrils that are based on
the glycoprotein fibrillin. There are also
a multitude of elastic fiber associated
molecules shown to be essential to

Figure 2.1. Elastin occurrence the body.
Elastic fibers are found predominantly in
connective tissues such as skin, lungs, and
blood vessels (Kielty 2002).

elastic fiber formation through knock-out animal studies such as lysyl oxidase
(LOX) (35, 36) and fibulin-4 (37) and -5 (8, 9). This chapter will provide a
background on the formation of elastic fibers, elastogenesis, and demonstrate
the need to better understand elastogenesis for tissue engineering applications.
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2.1 Elastin Fiber Structural Arrangement and Function
2.1.1 Chemical Composition of Elastic Fiber
Elastin is an extracellular matrix protein encoded by a single gene on the
human chromosome 7q11.23 codes for elastin (38). Elastin contains a highly
conserved amino acid sequence (VGVAPG), rich in a high concentration of nonpolar amino acids proline (10%) and glycine (33%) resulting in a hydrophobic
protein. Elastin contains additional amino acids such as OH-proline (1%), alanine,
valine, and leucine (40-50%) (39) as shown in Table 2.1. The polypeptide chains
in elastin are cross-linked by unique polyfunctional heterocyclic acids called
desmosine and isodesmosine, as opposed to typical disulfide bridges. These
distinctive internal linkages and inherent hydrophobicity make elastin a stable
protein, resistant to the normal breakdown characteristic of most proteins.
Elastin is secreted as a soluble monomer, tropoelastin, which has a
secondary structure characterized by alternating
hydrophobic (β-sheet) and hydrophilic (α-chain)
regions encoded by separate exons (40). The
secondary structure of elastin consists of 10% αhelices, 40% β-sheets, and 50% undefined

Table 2.1. Amino acid
composition of elastin
derived from bovine aorta.
Values are expressed as a
percentage of the total amino
acid residues. Desmosine and
Isodesmosine are expressed as
lysine equivalents (Balazs
1970).
Amino Acid
Percent

conformations (41). The hydrophilic regions are

Proline

11.27

Glycine

33.24

alanine- and lysine-rich, while the hydrophobic

Alanine

22.39

Valine

13.13

Leucine

5.82

Phenylalanine

2.97

Desmosine

0.96

Isodesmosine

0.55

domains are rich in proline, valine, and glycine
(42). Lysyl oxidase (LOX), a copper-dependent
enzyme (39), crosslinks targeting domains (43) of
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the α-helical regions, via desmosine and isodesmosine linkages (41), to yield a
crosslinked insoluble, yet flexible matrix protein.

2.1.2 Elastin ultrastructure
Elastin may be ultrastructurally organized into individual and networked
fibers (e.g., loose fibers and loose or compact meshes) or inter-woven, nonfibrillar matrix structures (e.g., continuous sheets, fenestrated sheets) (Scott
1996). The fibrillar structures contribute to the elasticity of the tissues that contain
them, allowing them to characteristically recoil, when distending forces are
removed.

Figure.2.2 Elastin organization can vary depending upon its mechanical and functional
role within different tissues. These differences in ultrastructure can be visualized with
scanning electron microscopy (SEM) (Scott 1996).

Elastic fibers (~200-900 nm diameter) are major insoluble ECM
assemblies deposited during early development in elastic connective tissues.
They are composed of a central core of cross linked, amorphous elastin
surrounded by microfibrils (Kielty 2002). The microfibrils are composed of a
number of different glycoproteins, predominately fibrillin, which are essential both
to maintain the integrity of the fibers and the ability of cells to interact and
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respond to them. Microfibrils are typically 10 nm in diameter with an average
periodicity of 57 nm (Lu 2006). They form linear bundles and are deposited as
pre- scaffolds onto which soluble tropoelastin monomers then coalesce and are
crosslinked. During the elastin deposition process, the microfibrils are displaced
to the periphery of the growing elastin fibers, and typically appear electron-dense,
as opposed to the electron lucent amorphous elastin.

2.1.3 Biochemical Roles of Elastin
In addition to rendering tissues elastic, vascular matrix elastin also
regulates vascular cell behavior (44, 45). Correlative studies have demonstrated
large changes in the composition and distribution of extracellular matrix (ECM)
components during tissue development, cell differentiation, and in response to
growth factor, hormone, and cytokines (46). Modulation of a variety of cellular
functions, including secretory activities and gene transcription, occurs via
interaction with the ECM. The ECM also serves as a reservoir for growth factors
and cytokines (44). Therefore, ECM proteins, such as elastin, may influence cell
development,

survival

(anchorage-dependent),

proliferation,

phenotype,

migration, differentiation, and function (47).
Elastin affects cell-fate. Some cell types are dependent upon anchorage to
the surrounding ECM for survival. Anchoring junctions, such as adherens
junctions and hemidesmosomes formed by integrin transmembrane proteins,
mechanically attach cells and their cytoskeletons to the ECM (48). Therefore, the
presence or absence of elastin may influence cell viability. The phenotype (the
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appearance

and

behavior

of

cells) also depends upon the
ECM. For example, in pathologic
conditions,

elastin

may

be

fragmented and the fragments
may encourage SMCs to change
from a contractile to a synthetic
phenotype.

Additionally,

cell

locomotion is affected by ECM

Figure 2.3. Elastin Fiber Structure. An individual
elastic fiber is composed of a core of aggregated
tropoelastin monomers surrounded by an outer
sheath of microfibrils. The microfibrillar scaffold is
primarily composed of the fibrillin proteins.

components, including elastin, and requires an initial polarization of the cell to
promote migration in a particular direction. Cell movement is in response to
chemical and physical cues in the cell environment. Therefore, the physical
properties of elastin influence cell movement, specifically inflammatory cells in
scenarios of disease.
Tropoelastin, the soluble elastin precursor, influences chemotaxis (Indik
1990), stimulates vasodilation53, regulates intracellular Ca2+ (Faury

1998),

and

promotes cell adhesion (Grosso 1991). Mature elastin also has numerous effects
on vascular SMCs including inducing actin stress fiber orientation, inhibiting SMC
proliferation, and regulating cell migration (Rodgers 2005).

2.2 Elastic Fiber Assembly
2.2.1. Formation of an Elastic Fiber
Mature elastic fibers are composed of a central core of elastin surrounded
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by glycoprotein microfibrils (10-12 nm in diameter) (49). During the early stages
of elastogenesis, these microfibrils are formed first in the extracellular matrix
(ECM) space and play a major role in organizing elastin into elastic fibers. The
major microfibrillar components are fibrillin -1 and -2 that polymerize in a head-totail manner to yield the microfibrils. Calcium binding stabilizes the linear and rigid
structure of fibrillin monomers, their interactions, the lateral packing of microfibrils,
and thus the three-dimensional organization of their macroaggregates. While the
ECM is organizing the microfibrillar scaffold for elastin deposition, the elastin
monomers are synthesized within the cell.

Figure 2.4 Elastogenesis involves the secretion of tropoelastin monomers to the
extracellular space. Within the cell, the elastin binding protein (EBP), a splace variant of
Beta galactosidase, binds to tropoelastin monomers to provide stability and prevent selfaggregation of elastin. EBP chaperones elastin where it is secreted through the plasma
membrane and binds to transmembrane proteins cathepsin A (PPCA) and neuraminidase 1
(NEU1) forming the elastin receptor. Betagalactosidase sugars can bind to the EBP causing
a conformational change and release of elastin into the extracellular matrix.

31

Figure 2.5 Fibulins facilitate the formation of elastic fibers through binding of elastin
monomers and transportation to the microfibrillar scaffold. Tropoelastin monomers are
crosslinked by lysyl oxidase (LOX) and aggregated forming the elastin-rich dense core of an
elastic fiber. Fibulins assist the transportation of tropoelastin as it is assembled on the fibrillin
rich scaffold that will form the outer sheath of the elastic fiber.

The soluble elastin precursor, tropoelastin, is first synthesized within the
cell and is chaperoned to the plasma membrane for secretion by the elastin
binding protein (EBP) which also prevents premature self-aggregating. EBP and
tropoelastin are secreted and EBP binds to two integral membrane proteins,
neuraminidase 1 and cathepsin A, on the cell surface that form a transmembrane
link between the extracellular compartment and the cytoskeleton (50) (Figure
2.4). The complex of EBP, neuraminidase 1, and cathepsin A is known as the
elastin receptor (51, 52) that tethers tropoelastin to the cell surface in the
extracellular space where it interacts with the microfibrils and becomes oriented
within a growing elastic fiber for eventual crosslinking (53) (Figure 2.5). EBP is
bifunctional in that it also has galactolectin properties. It binds the hydrophobic
VGVAPG sequence in elastin, the cell membrane, and galactosugars via three
separate sites. The binding of galactosugars lowers its affinity for both
tropoelastin and for the cell-binding site, resulting in the release of bound elastin
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and the dissociation of the 67
kDa

subunit

from

membrane.

the

cell

Galactosugar-

containing

microfibrillar

glycoproteins may therefore be
involved

in

the

coordinated

release of tropoelastin by the
cell (54) (Figure 2.4).
The

tropoelastin

Figure 2.6. Elastin conformational shift from
relaxation to stretch (2).

deposited onto the microfibril matrix is then crosslinked into mature elastin.
Crosslinking of elastin is initiated by the action of lysyl oxidase (LOX), a Cu2+
dependent endogenously produced enzyme that catalyzes the oxidative
deamination of lysine residues into allysine (55). This is the only enzymatic step
involved in elastin crosslinking. Subsequent formation of crosslinks between
tropoelastin molecules by desmosine and isodesmosine occurs as a series of
spontaneous condensation reactions, resulting in the production of a complete
elastic fiber. The relative proportion of microfibrils to elastin declines with
increasing age of the animal, adult elastic fibers having only a very sparse
peripheral mantle of microfibrillar material (56).
Elastin fibers form random coiled structural networks that allow them to be
stretched and then to recoil to their original state upon load-release (Figure 2.6).
Elastic fibers formed by such aggregation vary in thickness, length and threedimensional architecture depending on the direction and magnitude of the forces
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exerted upon the tissue. This morphological diversification can be seen in
different organ systems. In the aortic wall, elastic fibers form thick concentric
lamellae in the tunica media with interlaminar connecting fibers scattered radially.
Additionally, microfibrils are present as a complex meshwork throughout the
aortic wall. It can be generalized that the elastic fibers are responsible for dilation
and recoil, with the microfibrils acting as flexible links that make the aortic wall a
working unit (55).

2.2.2 Dynamics and Mechanical Properties of Elastin
The mechanical properties of blood vessels influence a broad spectrum of
physiologic phenomena, including blood pressure, flow rates, wall shear stress,
biomolecules,

and

mass

cell

transport

that,

in

turn,

critically

impact

cardiovascular
homeostasis.

As

mentioned
previously,

the

mechanical
properties

of

blood

vessels

stem

from

microstructural
wall components,
such as collagen

Figure 2.7. Stress-strain curve for a blood vessel demonstrates
the mechanical role of elastin in response to initial strain. The
blood vessel initially distends in response to strain as contributed by
elastin. At a certain strain the mechanical stress load is distributed to
the collagen fibers within the blood vessel and the blood vessel
becomes stiffer as evidenced by the sharp slope increase of stress to
strain (http://biochemistry.utoronto.ca/keeley/bch.html).
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and elastin fibers, smooth muscle cells, and fibroblasts (49). Since these
individual components take up loads at different stress levels, their source and
location-specific differences, content and distribution within blood vessels, and
their alteration in diseased states can render the mechanical properties of blood
vessels complex and difficult to predict. Collagen and elastin affect the
mechanical behavior of vessels in different ways (Figure 2.7). Strain is initially
accommodated by elastin allowing the vessel to expand with minimal resistance,
and, eventually strain is strongly resisted by collagen preventing overexpansion.
While collagen provides rigidity, elastin allows the connective tissues in blood
vessels to stretch and then recoil to their original positions. A study by Gundiah
et al. (57) has shown that axial elastin fibers in intimal and adventitial layers, and
circumferential medial fibers help distribute tensile stresses during vessel
inflation and relaxation, conclusively providing evidence that emphasizes
mechanical importance and indispensability of elastin fibers in the aortal anatomy.

2.3 Role of Extracellular Matrix Proteins in Elastogenesis
2.3.1 Fibulins as Regulators of Elastogenesis
Several members of the fibulin protein family also play important roles in
elastogenesis. For example, fibulin-5 (Fbln5) is essential to the incorporation of
elastin into the core of elastic fibers; Fbln5 knockout mice have been shown to
produce abnormal elastic fibers with elastin situated in globules on the surface of
the microfibril scaffold (58).

Although fibulin-2 (Fbln2) knockout mice do not

show an obvious phenotype, double knockouts of Fbln2 and Fbln5 exhibit a more
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severe phenotype than Fbln5 knockouts; the aortas of double knockout mice
have thin, disorganized internal elastic laminae and show abnormal repair after
injury (59).

2.3.2 Proteoglycans as Regulators of
Elastogenesis
A number of studies point to an
inhibitory role for certain proteoglycans
(PGs) in the assembly of elastic fibers
(60-62). Mechanistically, this is thought
to involve β-galactosugars PGs acting to
displace tropoelastin from the elastin
binding protein (EBP) (63). Indeed,
addition of either chondroitin sulfate (CS)
chains,

or

the

CS

PG,

versican,

Figure 2.8. Alternate splicing of
versican mRNA produces 4 distinct
isoforms. Versican V3 is the smallest
variant at 73 kDa and contains no GAG
attachment sites.

decreases elastic fiber formation (60). Furthermore, impaired elastic fiber
assembly is observed in Hurler disease and Costello syndrome in which there is
an accumulation of glycosaminoglycans (GAGs) (64). Similarly, increased elastin
accumulation has been achieved in the rat carotid artery by seeding of VSMCs
transduced to express a GAG-deficient form of the PG, biglycan (61).
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2.3.3 Versican V3 as a Regulator of Elastogenesis
Other extracellular matrix proteins have also been found to associate with
elastic fibers and affect the process of elastogenesis. One such molecule is
versican, a large chondroitin sulfate proteoglycan found in a variety of soft
tissues. Versican contains four main domains as shown in Figure 2.8. The Nterminal region binds to the glycosaminoglycan hyaluronan; aggregates of
versican and hyaluronan associate with the cell surface and influence cell shape,
cell division, and other processes. The C-terminal region serves a variety of
regulatory functions and binds to integrins and extracellular matrix components.
The remainder of the molecule is composed of two large regions containing
binding sites for chondroitin sulfate (65).
Four versican splice variants of varying length have been identified. The
full-length V0 isoform contains all four of the major domains, including both
chondroitin sulfate-binding regions. The V1 and V2 variants are missing the β
and α chondroitin sulfate-binding regions, respectively, and the V3 isoform
consists of only the N-terminal and C-terminal regions with no chondroitin sulfate
binding sites as shown in Figure 2.5.
Previous studies have shown that the chondroitin sulfate side chains of
proteoglycans such as versican can disrupt the process of elastogenesis, leading
to decreased elastin deposition in the extracellular matrix and abnormal elastic
fiber assembly (66). The V3 form of versican, however, lacks these inhibitory side
chains. In fact, the overexpression of V3 in arterial smooth muscle cells has been

37

shown to lead to increased elastic fiber formation in rat arterial smooth muscle
cells both in vitro and in vivo (67, 68).
Furthermore, V3 has been shown to promote elastogenesis and improve
the structural and functional properties of engineered vascular constructs (69).
The positive effects of V3 on elastogenesis have been attributed to its ability to
displace GAG containing variants of versican from binding sites in the vicinity of
elastic

fiber

assembly

complexes

(i.e.,

EBP-tropoelastin

complexes).

Consequently, the suppressive effects of GAG moieties would be relieved and
elastic fiber assembly would proceed.

2.4 Elastic Fibers in Vascular Disease
A common pathologic feature of vascular disease is the disruption of
elastic fibers and the accumulation of SMCs within the intima between the
endothelium and medial layer of the vessel wall resulting in the progressive
occlusion of blood flow. Under normal conditions, vascular SMCs in the tunica
media of blood vessels are quiescent and embedded in a network of elastin-rich
ECM that acts as a barrier to SMC migration and proliferation (70). During
atherosclerosis, different cell types, including ECs, platelets, and inflammatory
cells release mediators, such as growth factors and cytokines that induce
phenotype change of vascular SMC from the quiescent "contractile" phenotype
state to the active "synthetic" state, causing them to release matrix proteases
degrading the ECM (including elastin) allowing them to aggressively migrate into
the subendothelial space and contribute to neointima formation (71). The
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degradation of vascular elastin exposes other medial components (i.e. collagen,
SMCs) to very high tensile stresses (57). The high plasticity of SMCs makes
these cells susceptible to mechanically induced phenotypic changes that may
result in continued aggravated protease secretion and ECM degradation.
Since vascular SMCs modulate their phenotype readily, external factors in
the arterial wall must instruct them to maintain a quiescent, contractile state if
homeostasis is to be achieved. This regulation of vascular SMC activity occurs
through defined receptor interactions and signaling pathways. In contrast to other
matrix proteins, both in vitro and in vivo studies implicate elastin matrix as a
negative regulator of SMC activity within the arterial wall (72). Thus elastin
regulates vascular homeostasis by signaling SMCs through defined pathways to
localize around the elastic fibers in organized lamellar units and remain in a
quiescent, contractile state. The disruption of elastin by vascular disease, or
direct mechanical injury can interrupt cell-matrix signaling and directly upregulate SMC hyper-proliferation (70). The disruption of elastin is not simply an
end product of vascular disease, but an important contributor to the pathogenesis
of occlusive vascular disease. Preventing elastin matrix degradation following
vascular injury or restoring the lost/ degraded vascular elastin matrix is
imperative for vascular homeostasis restoration (72).
In disease states, wherein elastin has been broken down, the binding of
elastin peptides (the soluble products of elastin degradation) via the elastin
receptor (EBP and two other integral membrane proteins), G protein-coupled
receptors (GPCR), or other integrins results in activation of G proteins and
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opening of calcium channels (73). The Rho signaling cascade can be stimulated
by elastin and is mediated by GPCRs, the largest family of transmembrane
receptors (74, 75). A study by Karnik proposed a molecular mechanism for
vascular SMCs in which elastin activates a G-protein-coupled pathway (75),
inhibits adenylate cyclase, reduces cAMP levels (76), and stimulates Rho
induced actin polymerization (75).
Under pathologic conditions, such as in atherosclerosis and within
abdominal aortic aneurysms (AAAs), elastin breaks down to generate elastin
peptides at an accelerated rate. These elastin degradation products up-regulate
SMC proliferation and activate phagocytic cells (73). Elastin peptides are
released and through their interaction with receptors present on the surface of
fibroblasts, phagocytes, lymphocytes, SMCs, and endothelial cells (ECs) elicit a
variety of biologic effects such as matrix-metalloproteinase (MMP) overexpression, greater Ca2+ influx, enhanced vasorelaxation and chemotactic activity.
In atherosclerotic and neointimal lesions, SMCs migrate from the tunica media
through the internal elastin lamina to the intima. Protease release by these SMCs
is responsible for further elastin destruction in the arterial wall. Elastin is similarly
enzymatically degraded by MMPs in aneurismal vessels, specifically MMP-2 and
MMP-9 released by activated SMCs and infiltrated leukocytes, which leads to
formation of floppy, de-elastized vascular segments, susceptible to rupture (77).
The degradation of elastin is the result of a proteolytic cascade that involves the
cooperation of several degradative enzyme types such as serine proteases,
matrix metalloproteinases, and cysteine proteases (71). These may be present in
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latent forms under healthy physiologic conditions, yet become activated following
vessel wall injury.
2.5 Engineering Strategies to Promote Elastin Regeneration
Elastin is crucial to maintaining the native structural configuration (11, 7880) and regulating the cell-signaling pathways (12, 81-83) of blood vessels. Thus,
the failure to reinstate a healthy elastin matrix, when damaged by disease (e.g.,
inflammation-mediated elastin degradation in atherosclerosis) can severely
compromise vessel homeostasis (13). In addition to achieving functional and
complete endothelialization, a major concern in the development of tissueengineered vascular constructs is the ability of scaffolding materials to modulate
SMC behavior and encourage the regeneration of elastin-rich matrix.

2.5.1 Synthetic Scaffolds
The most widely used synthetic scaffolds are poly-lactic (PLA), polyglycolic acid (PGA), and poly-L-lactic acid (PLLA). Although these scaffolds are
not ideal from the standpoint of eliciting poor cell attachment, PLLA has been
shown to favor elastogenesis (84). SMCs seeded onto polyhydroxyalkanoates
synthesize uniformly aligned elastin and collagen fibers in the direction of blood
flow. Previous attempts by Stock et al. (85) to regenerate elastin on laminacoated PGA scaffolds in vitro, did not replicate the amounts and ultrastructure of
elastin, synthesized by the same scaffolds when implanted in vivo (85). This
underlies the absence of cell signals controlling elastin mRNA expression in vitro
and also leads to the conclusion that biosynthesis and crosslinking of elastin
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appears to be one of the most complex and tightly regulated processes during
blood vessel maturation. Application of mechanical stimuli (e.g., dynamic
stimulation), growth factors (e.g., TGF-β), and of stem cells (e.g., endothelial
progenitor cells) can upregulate amounts of elastin biosynthesis within synthetic
scaffolds but not to the extent of mimicking native arterial elastin (84). Thus,
biological scaffolds, and more importantly ECM scaffolds, which theoretically
would be expected to elicit more closely native cell responses have gained much
attention in the context of elastic tissue regeneration (84).

2.5.2 Biological Scaffolds
Biological scaffolds are normally fabricated from one or all the
components such as elastin, collagen, glycosaminoglycans and more recently
fibrin, which has been clinically approved for promotion of elastin biosynthesis
when incorporated in a three dimensional (3D) arrangement within scaffolds.
Each of these components differs in the levels of elastin biosynthesis they elicit.
Previous studies have shown enhanced elastin biosynthesis by rat neonatal
SMCs cultured onto hyaluronic acid gel scaffolds as compared to controls
(plastic) (84). Collagen scaffolds fail to regenerate substantial elastin in vitro even
in presence of seeded vascular SMCs. Long and Tranquillo showed higher levels
of elastin biosynthesis by neonatal vascular SMCs seeded onto fibrin scaffolds
and within fibrin-collagen constructs (86). Cells entrapped and cultured within 3D
fibrin gels allowed formation of complex elastin geometries similar to that
observed in native elastin. Although promising, above results were generated by
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neonatal SMCs and dermal fibroblasts; both cell types that retain high
elastogenic potential, unlike adult SMCs (87). Also, the organization of elastin
fibers into structural networks, and their mechanical properties were not
characterized. This study validates previous claims as to the overall superiority of
3D, ECM-based cell scaffolds over 3D synthetic scaffolds or two dimensional
(2D) monolayer cell cultures to efforts to simulate the chemical and physical
environment of tissues (86, 88). Cells within 3D scaffolds come into contact with
other cells and ECM in three dimensions and are therefore expected to more
closely evoke native cell responses than 2D substrates.
Lee et al. has demonstrated in a study involving SMCs seeded onto ECM
scaffolds that the phenotype of SMCs in engineered tissues is strongly regulated
by the chemistry of scaffold in vitro, as a result of which SMCs exhibited a
differential cell growth and ECM production depending upon the scaffold to which
they adhered (89). More specifically elastin production was stimulated on PGA
scaffolds, used as controls in comparison to enhanced collagen production onto
collagen I scaffolds (89). In this study 2D culture models still provide useful
information since trends in scaffold chemistry-dependent variations of cell
phenotype and matrix synthesis are maintained, but not necessarily to the same
levels, when translated into a 3D culture system. The physical and mechanical
characteristics of the scaffold are important only to exaggerate or dampen
scaffold-chemistry-dependent cell responses or direct the structural organization
of the synthesized matrix towards defined end goals (89). Since gene expression
of cells cultured within 3D scaffolds, as within native tissues, can be regulated by
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various scaffold-derived cues including cell adhesion molecules, growth factors,
and mechanical stimuli, ECM-based scaffolds are more likely to evoke native
integrin-ECM interactions and preserve the native cell phenotype; similar
variations in the type and extent of cell receptor-ECM ligand interactions with
different ECM molecules can profoundly influence cell phenotype and matrix (e.g.,
elastin) synthesis (86, 88, 90). Successful upregulation of elastin synthesis and
organization into mature elastic tissue is contingent on the selection of an
appropriate scaffold material from among a subset of ECM molecules shown to
actively facilitate elastogenesis in vivo
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CHAPTER THREE
A CYTOKINE AXIS REGULATES ELASTIN FORMATION AND DEGRADATION

Elastogenesis is the process by which elastin-containing fibers and
lamellae are formed. The process is subject to dynamic regulation during the
development of tissues such as the lung and aorta where elastin biosynthesis is
active in late stages of development and in the early postnatal period but is
subsequently attenuated (91-93). Steady state, basal levels of elastin expression
and breakdown remain low in adult tissues as well as in cells isolated from adult
tissues (94, 95). Elastin expression is reactivated in diseases such as pulmonary
hypertension, dermal elastosis, pseudoxanthoma elasticum, Buschke–Ollendorff
syndrome, Moyamoya disease, cigarette smoke- induced emphysema, severe
chronic obstructive pulmonary disease (COPD) and forms of progeria (34, 96103), although in many of these disorders the elastin produced is disorganized
and dysfunctional (32-34).
Much is known about the molecular mechanisms underlying elastin
formation in development and disease. This understanding has been advanced
through studies of the many human genetic disorders and pathologies of elastinrich tissues e.g., Costello syndrome (104), cutis laxa syndrome (105) and
Ehlers–Danlos syndrome (106). Studies of mouse models have contributed
greatly to our understanding of the genes involved in developmental elastin
formation (107-109). In addition, numerous positive and negative effectors of
tropoelastin expression and elastin formation have been identified through in vitro
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experimentation (Tables 3.1 and 3.2). Emerging from studies of elastin
biology/pathobiology is a cytokine regulatory axis comprised of pro- and antielastogenic cytokines. In the present review we focus on highlighting salient
components of this regulatory axis and their mechanisms of action on elastin
biosynthesis and degradation.

3.1 Cytokines that promote elastin formation
3.1.1 Transforming growth factor β-1 (TGFβ1)
TGFβ1 is a member of the TGFβ superfamily of cytokines. TGFβ
activation is normally kept under tight negative control through the process of
extracellular matrix sequestration/latency (110). Increased TGFβ1 signaling
drives pathogenesis of multiple diseases (e.g., fibrotic diseases of the liver,
kidney, lung and skin), most of which impact elastin formation and breakdown.
For example, TGF-β1 overexpression results in severe interstitial and pleural
fibrosis accompanied with increased deposition of elastin (111). Overexpression
of active TGFβ1 in experimental abdominal aortic aneurysms is associated with
preservation of medial elastin (112) Indeed, numerous studies have established
that TGFβ1 augments both tropoelastin mRNA abundance (113-116) and elastin
formation (115, 117). Mechanistically, TGFβ1 mediates these effects by
modulating tropoelastin promoter activity, mRNA stability and elastin degradation.
A number of studies demonstrate that TGFβ1 exerts positive effects on
tropoelastin transcription. In human embryonic lung fibroblasts, TGFβ1 activates
tropoelastin transcription via the phosphatidylinositol 3-kinase/Akt/p38 signaling
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pathway

(118).

In

transgenic

mice

expressing

a

chloramphenicol

acetyltransferase (CAT) reporter gene under control of the human elastin
promoter, CAT activity is greatly elevated in the skin of TGFβ1 treated animals
(119). Furthermore, in chick embryo aorta cells transfected with an elastin
promoter-CAT construct, CAT activity is increased by addition of TGFβ1 (120).
By contrast, elastin promoter/CAT reporter studies performed in skin fibroblasts
showed that TGFβ1 did not change the promoter activity (121). These and other
findings indicate that the effects of TGFβ1 on elastin transcription are cell-type
specific. Consistent with this conclusion are findings of McGowan (122) showing
that TGFβ1 stimulates elastin formation in neonatal lung fibroblasts but not in
adult lung fibroblasts or adult lung smooth muscle cells. Furthermore, embryonic
aorta cells and tendon fibroblasts also display differential responsiveness to
TGFβ1 (120). These differential effects have been attributed to cell type-specific
nuclear transcription factors that bind to a TGFβ1-responsive element located in
the −196 to −12 region of the elastin promoter (120, 123).
TGFβ1 also acts post-transcriptionally to stabilize tropoelastin mRNA
transcripts (121, 124). Indeed, TGFβ1 can relieve tropoelastin mRNA instability in
cutis laxa fibroblasts in which tropoelastin mRNA is highly unstable (116).
Mechanistically, this involves a regulatory GA-rich sequence located in the 3′
UTR of the tropoelastin transcript referred to as the G3A site (125, 126).
Individuals of several families with inherited cutis laxa have mutations in the
tropoelastin gene located in the vicinity of the coding sequencing for this
regulatory element (i.e., located near the 5′ end of exon 30) (125). Elements
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related to the elastin GA-rich sequence are enriched in stable RNAs of other
genes and mediate binding of mRNA stability factors, including CUGBP1 (127).
Whether CUGBP1 or another such protein binds to the G3A site and influences
decay of the tropoelastin mRNA and whether TGFβ1 influences binding to the
site remain to be established.
The tropoelastin mRNA stabilization effects of TGFβ1 are mediated
through several TGFβ signaling pathways including the Smad signaling pathway,
the phosphatidylcholine (PC)-specific phospholipase C (PLC)-protein kinase C
(PKC)-delta pathway and the TGFβ-activated kinase (TAK1)-stress-activated
protein kinase p38 pathway (124, 128). This is supported by evidence showing
that TGFβ-stimulated tropoelastin mRNA accumulation can be blocked by
inhibitors of PLC, PKC and p38 as well as by transgenic expression of the
inhibitory Smad, Smad7 (128).
TGFβ1 may also stabilize elastin mRNA by reducing the expression of
microRNAs. Recent studies show that expression of the microRNA, miR-29, is
reduced by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR29 (130, 131). Furthermore, miR-29 mimics decrease elastin mRNA levels in
dermal fibroblasts and vascular smooth muscle cells (132). Moreover, in the
developing mouse aorta, an upregulation in the expression of miR-29 as well as
several other microRNAs that have targets in the elastin mRNA (i.e., the miR-15
family members miR-195 and miR-497) accompanies the downregulation of
elastin mRNA in the period between the newborn and adult (130, 131).
The ability of TGFβ to augment elastin expression also relates to
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hyaluronan signaling. Studies have shown that TGFβ1 and hyaluronan oligomers
(consisting of 3 to 9 glucuronate and N-acetylglucosamine disaccharides) act
synergistically to enhance elastin levels in the extracellular matrix of cultured
vascular smooth muscle cells (133). Intriguingly, TGFβ treatment of vascular
smooth muscle cells from experimentally induced aortic aneurysms does not
elicit a change in elastin synthesis, but treatment with a combination of TGFβ and
hyaluronan oligomers enhances elastin protein levels in the extracellular matrix
(134). Hyaluronan oligomers interact with the major receptor for hyaluronan,
CD44, and it is thought that hyaluronan oligomers disrupt endogenous
hyaluronan interactions with CD44 (135). Since CD44 has direct and indirect
interactions with other signaling receptors, including TGFβ receptor type I and
epidermal growth factor receptor (EGFR), disruption of hyaluronan-CD44 binding
can influence the activity of a variety of downstream signaling pathways. The
CD44-EGFR interaction may be of particular relevance to the pro-elastin effects
of hyaluronan oligomers since EGFR signaling appears to be anti-elastogenic
(136). Thus, hyaluronan oligomers may interfere with suppressive effects of
EGFR signaling on elastin expression. Studies describing EGFR signaling effects
on elastin are discussed below.
TGFβ1 also limits elastin degradation by decreasing levels and activity of
elastolytic proteases including matrix metalloproteinase (MMP)-2 and -9 (112).
Indeed, TGFβ blockade exacerbates elastin degradation and decreases levels of
elastin in medial layers of blood vessels (137). By contrast, overexpression of a
mutated, active form of TGFβ1 in animals having experimentally induced aortic
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aneurysms leads to reduction in the expression of elastolytic MMPs and
preservation of elastic fibers in the medial layers of injured aortas (112). TGFβ1
also elicits effects on MMP activity by augmenting expression of tissue inhibitors
of MMPs (TIMPs) (138). Similarly, TGFβ1 sustains levels of the plasmin inhibitor,
PAI-1, which prevents activation of the elastolytic protease MMP-9 (137, 139).

3.1.2 Insulin-like growth factor-I (IGF-I)
IGF-1 has been implicated as a positive regulator of elastogenesis
occurring in the developing aorta (140, 141) and in pathologies including
atherosclerosis (142). Like TGFβ, IGF-I elicits positive effects on elastin
expression (143-145). Also similar to TGFβ, the effects of IGF-I on elastogenesis
appear to be cell type specific. For example, IGF-I increases steady state levels
of tropoelastin mRNA and soluble elastin production in neonatal aortic smooth
muscle cells, but it elicits no change in tropoelastin expression in pulmonary
fibroblasts, which also express the type I IGF-I receptor (144).
IGF-I regulation of elastin expression involves the interaction of two
members of the Sp-family of transcription factors, Sp1 and Sp3, with elements of
the elastin promoter (142, 145-147). These transcription factors have opposing
effects on elastin transcription such that Sp1 promotes elastin transcription
whereas Sp3 represses Sp1-mediated enhancement of elastin transcription. IGFI acts to both promote Sp1 binding to the elastin promoter and abrogate Sp3
interaction with the elastin promoter (142).
Key to the process by which IGF-I mediates Sp1 interaction with the
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elastin promoter is the formation of a complex between Sp1 and phosphorylated
retinoblastoma protein (Rb) (142, 145-147). IGF-I acts to promote the formation
of a cyclinE–cyclin-dependent kinase 2 (cdk2) complex, which mediates cdk2dependent

phosphorylation

of

Rb

on

threonine-821

(Thr821)

(147).

Phosphorylation of Rb(Thr821) recruits Sp1 to Rb. The resulting complex binds
to a retinoblastoma control element within the elastin gene promoter and
stimulates tropoelastin transcription (147).
Intriguingly, the IGF-I-induced effects on Rb phosphorylation and elastin
expression are counter balanced by pro-proliferative stimuli transmitted through
the mitogenic Ras/MEK/ERK pathway. For example, dermal fibroblasts treated
with the mitogen, PDGF-BB, display decreased levels of phosphorylated
Rb(Thr821) and reduced elastin deposition (147). PDGF-BB also increases
Table 3.1: Effectors that augment elastin biosynthesis in cultured cells.
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levels of phosphorylated Rb(Ser780), which is elevated in Costello syndrome
fibroblasts that display H-Ras driven proliferation and decreased elastogenesis.
Quenching of the increased proliferation of Costello syndrome fibroblasts by
treatment with inhibitors of Ras, MEK or cdk4 induced up-regulation of
Rb(Thr821) phosphorylation, decreased Rb(Ser780) phosphorylation and
recovery of their elastogenesis deficiency (147). These findings fit with
observations indicating that an inverse relationship exists between elastin
deposition and cell proliferation (14).

3.2 Cytokines that inhibit elastin formation
3.2.1 Basic fibroblast growth factor (bFGF)
Basic fibroblast growth factor (bFGF, also known as FGF2) is a major
negative regulator of elastogenesis. bFGF decreases elastin gene transcription in
aortic smooth muscle cells (148) and pulmonary fibroblasts (149). Furthermore,
in mice bearing compound deficiency of the FGF receptors, 3 and 4, elastin
deposition is not downregulated postnatally in the lungs (150). While these
findings highlight that FGF signaling plays a role in attenuating developmental
elastogenesis in the lung, it is unclear whether this involves bFGF or other FGFs.
bFGF is the candidate elastin suppressor in the periodontal ligament (PDL), in
which elastin expression is normally negligible. bFGF is expressed in the PDL
(151) and has been shown to suppress transcription of tropoelastin in cultured
PDL cells (152). Interestingly, PDL cells grown in culture express tropoelastin
mRNA (152), suggesting that the suppressive mechanism operative in the PDL in
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vivo is released when the cells are placed in culture.
bFGF represses elastin gene transcription by augmenting expression of
the transcription factor Fra-1 (also known as fos-like antigen 1), that
subsequently binds to a sequence located at −564 to −558-bp in the elastin
promoter, heterodimerizing with c-Jun to form an inhibitory complex (153). bFGFdependent repression of tropoelastin mRNA expression can be blocked by
inhibition of MEK1, indicating that the MEK/ERK pathway mediates the response
of the growth factor (154).
The potent suppressive effects of bFGF may underlie attenuated/
defective elastogenesis observed in wound healing processes in which bFGF
levels are increased, such as in dermal, cerebral, hepatic, renal and tendon
wound healing (155). bFGF expressed in these in vivo settings or even in
cultured cells may oppose the action of positive effectors of elastogenesis.
Indeed, bFGF has been shown to inhibit the ability of TGFβ1 to induce elastin
expression by vascular smooth muscle cells (156). The suppressive effects of
bFGF on elastogenesis would appear to be an unfavorable consequence to
therapeutic use of bFGF in wound healing, if elastin synthesis is a desired
endpoint.
bFGF has also been shown to decrease the expression of mRNA
encoding lysyl oxidase (157), the enzyme that catalyzes tropoelastin crosslinking.
Interestingly, lysyl oxidase inactivates bFGF through promoting covalent
crosslinking of bFGF monomers to form multimers (158). It is not known whether
lysyl oxidase might cross link bFGF to elastin, but bFGF is released by elastase
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treatment of cultures of pulmonary fibroblasts and pulmonary artery smooth
muscle cell (149, 159), suggesting that the growth factor may be bound to elastin.
Release of extracellular matrix-bound bFGF has also been reported to occur in
response to burn injury of skin, another tissue rich in elastin (160). Elastase
release of bFGF could contribute to impaired elastin synthesis in pulmonary
obstructive diseases in which elastase degradation of elastin is operative.

3.2.2 Heparin-binding epidermal growth factor (HB-EGF)
HB-EGF is an EGF receptor (EGFR/ErbB1) ligand that reduces
tropoelastin mRNA expression and matrix accumulation of elastin protein (161,
162). HB-EGF mediates these effects through a mechanism that, like bFGF,
involves stimulation of ERK1/2 phosphorylation and nuclear accumulation of Fra1 (162). This is supported by findings showing that siRNA suppression of HBEGF expression leads to increased levels of elastin protein and decreased levels
of Fra-1 protein (161). In addition, other findings show that inhibition of ERK1/2
activation using MEK1/2 inhibitors reduces both HB-EGF-induced Fra-1
accumulation and HB-EGF-downregulation of tropoelastin mRNA expression
(162). HB-EGF also induces the expression of bFGF, which could amplify the
suppressive effects of HB-EGF on elastin expression (162).

3.2.3. Epidermal growth factor-like growth factor (EGF)
EGF is a cytokine produced in response to injury (163, 164). EGF and
TGFα-like cytokines are released by neo- natal rat lung fibroblasts treated with
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neutrophil elastase, a protease associated with excessive elastolysis in
emphysema (165). Similar to the action of HB-EGF, EGF causes decreases in
tropoelastin mRNA stability and insoluble elastin deposition (136, 166).
Tropoelastin mRNA destabilization by EGF can be blocked by the EGFR inhibitor,
AG1478, and the MEK/ERK inhibitor, U0126 (136). Dicamillo et al. (2006)
concluded that the EGFR/MEK/ERK signaling cascade acts in opposition to
TGFβ1 signaling to override the positive effects of TGFβ1 on tropoelastin mRNA
stability.

3.2.4 Transforming growth factor-α (TGFα)
TGFα is an EGFR ligand that is expressed by airway epithelial and
interstitial cells following lung injury (164, 167, 168), including the pathogenesis
of cystic fibrosis lung disease (169). TGFα is thus implicated in the elastolysis
and defective elastin repair associated with pathological remodeling of the lung.
Indeed, overexpression of TGFα in the neonatal lung leads to disorganized and
fragmented elastin fibers in the alveolar septae (170). Like EGF, TGFα is
released by lung fibroblasts in response to neutrophil elastase treatment, causing
tropoelastin mRNA destabilization via activation of the EGFR/MEK/ERK signaling
cascade (136, 171).

3.2.5 Tumor necrosis factor-alpha (TNF-α)
TNF-α, a proinflammatory cytokine, suppresses tropoelastin mRNA levels
in skin fibroblasts, aortic smooth muscle cells and lung fibroblasts (121, 165).
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Conversely, TNF-α knock- out mice display increased vascular elastin expression
(172), which may account for findings that TNF-α-deficient mice are resistant to
aneurysm formation (173).
In cultured aortic smooth muscle cells, the inhibitory effects of TNF-α on
elastin gene expression involve the transcription factor AP-1 binding to a region
in the elastin promoter located between −290 and −198 bases pairs (113). AP-1
complexes are heterodimers of Jun and Fos family members, each activated via
the MAP kinase signaling pathway. As mentioned above, bFGF exerts its
repressive effects on elastin transcription via the Fos family member Fra-1 (153),
downstream of MEK1/ERK1/2 pathway signaling (154). It is therefore possible
that TNF-α also downregulates tropoelastin transcription via MAP kinase
pathway effects on AP-1.
Another dimension to the relationship between TNF-α and elastin is that
TNF-α promotes elastin breakdown through enhanced release of elastolytic
enzymes (174-176). For example, TNF-α induces production of the elastolytic
MMPs, MMP-2 and MMP-9, by vascular smooth muscle cells (177).
Like EGF, TNF-α is released by lung fibroblasts in response to neutrophil
elastase

treatment

and

has

been

shown

to

abrogate

TGFβ-induced

enhancement of tropoelastin mRNA expression (121, 165). Enhanced TNF-α
expression also occurs in response to cigarette smoke exposure and its increase
correlates with pulmonary elastin breakdown, a precursor to emphysema (178).
TNF-α induced elastin degradation is also linked to vasculitis stemming from
Kawasaki disease as well as vascular aneurysms (179). In fact, in Lactobacillus
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casei cell wall extract-induced coronary arteritis, abrogation of TNF-α activity by
TNF-α-blocking agents or deletion of the TNF receptor-1 protects against elastin
degradation and aneurysm formation (179). Furthermore, doxycycline, which
inhibits MMP-9 enzymatic activity, can mitigate TNF-α-induced coronary elastin
breakdown (180).

3.2.6 Interleukin (IL)-1β
IL-1β is a pro-inflammatory cytokine released in pathologies involving
elastin-rich tissues (e.g., COPD and asthma) (181). Similar to TNF-α, IL-1β
enhances the release of elastases in skin and uterine fibroblasts (182, 183).
Induction of elastase expression may underlie the disruption of elastin fibers
observed in alveolar septa of mouse lungs induced to express IL-1β (184, 185).
Moreover, mice deficient in a negative regulator of IL-1β signaling, interleukin-1
receptor antagonist, develop femoral artery aneurysms displaying degradation of
both the internal and external elastic lamina (186).
In addition to its effects on elastase expression, IL-1β causes changes in
elastin transcription. In neonatal lung fibroblasts IL-1β reduces elastin gene
transcription (187, 188). The mechanism by which elastin transcription is
negatively regulated in response to IL-1β is most thoroughly defined in neonatal
lung fibroblasts. In these cells, IL-1β promotes nuclear localization of the p65
subunit of NF-κβ that subsequently interacts with Sp1 to downregulate elastin
transcription (188). This is supported by findings showing that: 1) overexpression
of p65 downregulates tropoelastin mRNA levels (188), and 2) that inhibition of
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NF-κβ blocks the effects of IL-1β on elastin transcription in neonatal rat lung
fibroblasts (189). Similarly, other studies show that p65 binds Sp1 proteins and
interferes with transcription of at least one other extra- cellular matrix protein,
type α1(I) collagen (190).
The effect of IL-1β on NF-κβ also increases the expression of the
transcriptional repressor CCAAT/enhancer-binding protein (C/EBP)-β (LIP),
which binds to a GCAAT-containing sequence located at −56 to −62 bp in the
elastin promoter (189). Like IL-1β, C/EBPβ protein levels are increased in lung
Table 3.2: Effectors that inhibit elastin biosynthesis in cultured cells.
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fibroblasts exposed to cigarette smoke (191). Importantly, levels of C/EBPβ
proteins are regulated in lung fibroblasts by the ubiquitin-proteasome path- way,
and

proteasome

inhibitor

treatments

downregulate

tropoelastin

mRNA

expression (192). C/EBP family members also bind to Rb, and the complexes
bind to C-EBP binding sites on DNA (193). Whether Rb-C/EBP proteins interfere
with the pro-elastin transcriptional activity of Rb-Sp1 remains to be determined.

3.3 Cytokines that have dual effects on elastin formation
3.3.1 IL-1β
By contrast to the anti-elastogenic effects exerted by IL-1β on neonatal
lung fibroblasts, several studies show that IL-1β promotes tropoelastin mRNA
expression in adult dermal fibroblasts (194, 195). For example, in dermal
fibroblasts isolated from transgenic mice expressing the human elastin promoter
linked to a CAT reporter, IL-1β increases CAT activity (194). Furthermore,
subcutaneous IL-1β injection into these transgenic mice increases CAT activity in
the skin, indicative of a robust positive effect on elastin transcription (196). The
molecular basis for the effects of IL-1β on elastin expression in skin fibroblasts is
not clear.

3.3.2 TGFβ
Despite the preponderance of evidence indicating that TGFβ is a proelastogenic factor, increased TGFβ activity as seen in Marfan syndrome (MFS)
(197) is associated with elastic fiber degeneration and decreased tropoelastin
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mRNA levels (198). This, together with the fact that noncanonical, Smadindependent,

TGFβ-mediated

Erk1/2

activation

drives

aortic

aneurysm

progression in MFS (199), appears to indicate that TGFβ signaling through the
noncanonical, Smad-independent, MAP kinase pathway has suppressive effects
on elastin RNA levels.

3.4 Conclusions
The cytokine-governed elastin regulatory axis is comprised of pro- and
anti-elastogenic cytokines that control the biosynthesis and break- down of
elastin through transcriptional and post-transcriptional mechanisms. How
cytokines exert opposing effects on elastin transcription (Fig. 1) hinges on the

Figure 3.1. Cytokine signaling cascades that influence tropoelastin transcription.
Cytokines and signaling pathway intermediates highlighted in red act to suppress tropoelastin
transcription. Cytokines and signaling pathway intermediates highlighted in green act to
promote tropoelastin transcription. RTK, receptor tyrosine kinases.
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way in which they influence cell cycle regulatory constituents, particularly cyclincyclin dependent kinase complexes and their substrates. For example, cytokines
such as IGF-I induce tropoelastin transcription by promoting cyclin E/cdk2dependent phosphorylation of Rb(Thr821) which recruits Sp1 to bind the elastin
gene promoter and stimulate transcription (147). Counterbalancing this process
is mitogenic cytokine signaling via the Ras/MEK/ERK cascade. Cytokines such
as EGF, HB-EGF and TGFα, which stimulate this cascade through activation of
EGFR, exert suppressive effects on elastin biosynthesis and/ or catabolism.
Likewise, Ras/MEK/ERK pathway signaling mediated by bFGF, PDGF-BB and
TNF-α also elicit suppressive effects on elastin expression, as does noncanonical,
Smad-independent Ras/MEK/ERK signaling stimulated by TGFβ1. Importantly,
cytokine stimulated Ras/MEK/ERK signaling acts in opposition to the pro-elastin
effects of canonical TGFβ1 signaling, possibly through attenuation of nuclear
accumulation of activated SMADs (200). Similarly, Ras/MEK/ERK-mediated
initiation of the cell-cycle progression acts to attenuate the elastin transcriptionpromoting effects of IGF-I.

61

CHAPTER FOUR
DNA MICROARRAY BASED TRANSCRIPTOMIC PROFILING TO IDENTIFY
GENES THAT ARE SIMILARLY REGULATED IN PROCESSES IN WHICH
ELASTOGENESIS IS A KEY COMPONENT

4.1 Introduction
DNA microarray technology is a high-throughput quantification of the
expression of thousands of genes at the same time within a sample. The
technology is based on a DNA chip containing thousands of DNA probes (oligos),
each containing on the order of picomoles of a section of DNA sequence
localized to a specific location on the chip. The chip comes into contact with copy
DNA (cDNA) created from an experimental sample and cDNAs hybridized to the
probes. Probe-target hybridization can then be detected and quantified by
fluorophore-labeled targets. DNA microarray analyses generate vast amounts of
data on expression intensities within the sample for each DNA probe present on
the chip. The advent of this massive data-generating assay results in endless
approaches to data analysis.
This technology is novel in that it enabled quantification of the coexpression of sets of genes in a given tissue in given conditions that can be
analyzed to predict gene regulatory networks. DNA Microarray studies suggest a
correlated action of different elements of the gene regulation machinery and their
potential interaction. The information gained offers an unprecedented opportunity
to fully characterize biological processes.
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4.2 Materials and Methods
4.2.1 Identification of Processes in which Elastogenesis as a Key Component.
The formation of elastic fibers, elastogenesis, is prominent in fetal and
postnatal development but adult fibroblasts do not assemble elastic fibers under
normal conditions (201, 202). During elastogenesis the elastin gene is
upregulated from a quiescent state and then returns to a baseline level. We
identifie processes where the elastin gene is upregulated as in the window of
development.
Elastic fibers synthesized during development are considered the gold
standard by which wound injury elastic fibers and in vitro elastic fibers are
compared and of the quality that tissue engineers aspire to synthesize. However,
considering other processes in which elastin is a key component is essential in
order to further refine the “elastogenic developmental set” and to eliminate genes
that are specific to development and inessential to elastogenesis. In vivo
processes for consideration occurred in tissues in which mature elastic fibers are
a primary component. Microarray data from in vitro cell culture was selected in
cells that synthesize elastic fibers in their derived tissue in vivo (i.e., vascular
smooth muscles cells (VSMCs), fibroblasts, etc.) (21-24).
Criteria for determining processes in which elastogenesis is a key
component relied upon 1) the process occurs in a recognized elastic fiber
containing tissue or elastin producing cell as determined by histological literature
and 2) the elastin gene is significantly upregulated over a time course.
It is a recognized risk that comparison of commonly regulated genes from
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lower quality or defective elastic fibers may exclude certain critical genes. It is
also a possibility that identification of significantly regulated genes in an opposing
direction to development may elucidate genes responsible for elastic fiber
defects in wound repair and in vitro.

4.2.2 Transcriptomic Profiling During Developmental Models
The formation of elastic fibers, elastogenesis, is prominent in fetal and
postnatal development and developmental elastin fibers are the gold standard by
which tissue engineered elastin fibers are compared. It is therefore essential to
understand the biological processes occurring during elastogenesis through DNA
microarray analysis of simultaneous gene expression during development of
elastin-containing tissues of animal models.

4.2.2.1 Transcriptomic Profiling of the Developing Lung
Elastogenesis primarily occurs during development with elastin produced
in the lung during late fetal, neonatal, and early postnatal growth coinciding with
alveolarization (91). Tropoelastin mRNA is barely detectable in the adult lung.
We isolatee RNA from C57BL/6
mouse

lung

tissue

from

postnatal day (d) 5 to adult (8
months)

at

5

developmental

stages (4 samples/stage) before,
during and after elastogenesis.

Figure 4.1. Elastin expression profile in
developing rodent lung. A study by Chailley-Heu
illustrates a developmental peak in elastin
expression profile in postnatal rat lung by Northern
blot showing an increase in elastin expression
corresponding to alveolar septation in the rat (1)
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4.2.2.1.1 RNA Preparation from Developing Lung Tissue
Lungs from wild type C57BL/6 mice were extracted for RNA preparation at
5, 7, 10, 14, and 225 days postnatal (n = 3 for each time point, n = 4 for 225
days). Mice aged 5, 7, and 10 days postnatal were sacrificed by decapitation,
mice aged 14 days were sacrificed by CO2 inhalation followed by cervical
dislocation, and adult mice aged 225 days postnatal were sacrificed by isoflurane
inhalation followed by cervical dislocation according to standard laboratory
protocols approved by the Animal Research Committee at the Medical University
of South Carolina and at Clemson University. For each mouse, the left lung was
removed and stored in RNALater® solution pending RNA extraction. Due to
protocol concerning differences in lung function at various time points, It was not
possible to control the euthanation procedure variations prior to lung tissue
extraction. Neonatal animals have underdeveloped lungs that would not respond
to CO2 inhalation while it would be inhumane not to treat adult animals otherwise.
It is possible that the inhalation procedure variations could contribute to
differences in gene expression but efforts were taken to act fast minimizing the
effects of chemicals on lung tissue.
For each mouse, a maximum of 30 mg lung tissue was homogenized in
Trizol® reagent and extracted with 0.2 mL chloroform per mL Trizol. Total RNA
was extracted from the aqueous phase of each sample with a Qiagen RNeasy®
Plus Mini Kit according to the manufacturer’s instructions. The RNeasy
technology combines the selective binding properties of a silica-based
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membrane with the speed of microspin technology. Genomic DNA was removed
in a single, rapid centrifugation step by passing each sample over a gDNA
eliminator column. RNA longer than 200 bases within the sample is then bound
to the RNeasy silica membrane with a specialized high-salt buffer system while
contaminants are efficiently washed away. High-quality RNA was eluted in 30 µl
water of which 1 uL was used to measure concentration and quality with a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).

4.2.2.1.2 Synthesis of Biotin-Labeled cRNA Targets and Hybridization to
Affymetrix Gene Chips
Synthesis of double-stranded cDNA from RNA, in vitro transcription of
biotin-labeled cRNA targets, and fragmentation of target cRNA were performed
as outlined by Affymetrix protocols (Affymetrix, Santa Clara, CA). Fragmented
cRNA samples were hybridized overnight at 45°C to Affymetrix Mouse GeneChip
MG_U74Bv2. Posthybridization washing and phycoerythrin-streptavidin staining
and fluorescence scanning were performed using Affymetrix instrumentation in
accordance with manufacturer protocols.

4.2.2.1.3 Analysis of DNA Microarray Data
The resulting scans (CEL files) containing gene hybridization intensities
were normalized using Robust Multichip Average (203) implemented with the
ArrayQuest web-based analysis system. Normalized hybridization values were
imported into the analysis tool dChip 2005 (204) for subsequent analysis. Gene
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probe IDs differentially expressed during lung development were identified using
both statistical analysis and presence thresholds. Statistical analysis was
performed

with

Significance

Analysis

of

Microarrays

(SAM,

www-

stat.stanford.edu). In this analysis, a gene was determined to be differentially
regulated if the false discovery rate (FDR) < 5%. A gene was considered
“present” if at least two of three samples per timepoint had non-absent calls (P or
M) in at least one timepoint.

4.2.2.2 Transcriptomic Profiling of Developing Aortic Tissue
Tropoelastin expression in the aorta occurs at the end of embryonic
development through one month postnatal development in mice (205, 206). Dr.
Robert Mecham (Washington University School of Medicine, St. Louis, MO)
contributed raw DNA microarray data on Affymetrix MG_U74Bv2 chips
(unpublished) from an analysis of mouse aortae ranging from embryonic day 14
to postnatal day 180. There was 1 sample (each a pool of 3 aortas) for each
developmental stage. Statistical analysis was performed by standard deviation
across a gene probe > 0.5 and having a gene presence call > 20% for
developmental stages of a particular gene probe.

4.2.3 Transcriptomic Profiling During Injury Models
One challenge to microarray analysis of developmental models is to
distinguish which processes are important for specific elastic fiber formation and
which represent general changes that occur during development. This issue was
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addressed with incorporation of additional animal models in which elastic fiber
formation occurs such as during wound healing processes. The goal was how to
distinguish the elastic fiber formation-specific pathways from developmental
regulatory pathways.

4.2.3.1 Transcriptomic Profiling of a Lung Injury
Transcriptome data was analyzed from a time course of mouse lung injury
induced by intraperitoneal injection of naphthalene (31). Naphthalene injection
had been shown to selectively kill Clara cells in the lung while leaving bronchiolar
stem cells intact, allowing these cells to repair the damaged tissue and fully
restore the epithelial layer (207). Due to the high levels of elastic fibers present in
the lung, a model of lung repair that fully restores a normal epithelium should
show significant expression changes in genes related to elastic fiber formation
Mouse lungs were injected with naphthalene and lungs collected in at 1 d,
2 d, 3 d, and 6 d post-injection and compared to saline-injected control mice (n=4
samples/timepoint) and microarray analysis was performed at the University of
Pittsburgh Cance Center Clinical Microarray core using Codelink 20K Mouse
Bioarrays (Applied Microarrays, Tempe, AZ). Microarray data files (CEL files)
were obtained from the National Center for Biotechnology Information Gene
Expression Omnibus (NCBI GEO) Datasets website. The processed data had
been log2 transformed and normalized to the geometric mean across all
samples. The online CNIO IDconverter tool was then used to obtain gene
symbols and EntrezGene IDs from the provided GenBank Accessions for all
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transcripts (208). Analysis of variance (ANOVA) was used to statistically
compare each post-injury time point (n = 4 for each time point) and control lung
samples (n = 4) with alpha set at 0.05. This means that if a p-value for a gene
probe is < 0.05 then the null hypothesis that there is no difference between
timepoints is rejected. A gene probe was determined to be “present” if at least
two of four samples per timepoint had non-absent calls (P or M) in at least one
timepoint.

4.2.3.2 Transcriptomic Profiling of a Skin Injury
In order to eliminate organ specific gene expression in an injury model, we
identified another injury model in an elastin-rich organ, the skin. Gene expression
during wound healing by punch biopsy in the mouse skin was observed in
various stages of healing from 1 to 6 days post-injury (209). The wound healing
of the skin after an injury involves the formation of elastic fibers, however the
quality of the fibers is less than optimal with disorganization and an increase in
fibrosis resulting in some scar tissue. For our studies, we obtained the raw
microarray data from the National Center for Biotechnology Information Gene
Expression Omnibus (NCBI GEO) Datasets website.
CEL files for the microarray analysis were downloaded from the NCBI
GEO Datasets website and normalized by the Robust Multichip Average (RMA)
method using Affymetrix Expression Console software. To be considered
present, a gene must be called present in at least two of the three control
samples and in at least two out of three samples in one of the post-injury time
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points. Analysis of variance (ANOVA) was used to statistically compare each
post-injury time point (n = 3 for each time point) and control lung samples (n = 3)
with alpha set at 0.05. This means that if a p-value for a gene probe is < 0.05
then the null hypothesis that there is no difference between timepoints is
rejected. A gene probe was determined to be “present” if at least two of three
samples per timepoint had non-absent calls (P or M) in at least one timepoint.

4.2.4 Transcriptomic Profiling During In Vitro Elastic Fiber Formation
One challenge to microarray analysis of animal models is to distinguish
which processes are important for specific elastic fiber formation and which
represent general changes that occur in a complex living organism. This issue
was addressed with incorporation of the following in vitro culture model in which
versican variant V3 stimulates elastic fiber formation in vascular smooth muscle
cells (VSMCs). The goal was how to identify the elastic fiber formation-specific
pathways from the total changes in gene expression.

4.2.4.1 Versican V3-transduction of Vascular Smooth Muscle Cells (VSMCs)
Versican, a large (>1000kDa) chondroitin sulfate proteoglycan is found in
the extracellular matrix (ECM) of a variety of soft tissues. The smallest (73kDa) of
the 4 identified splice variants has been reported to augment tropoelastin
expression and elastic fiber formation in rat VSMCs(210), however the
mechanism by which V3 overexperession upregulates elastogenesis is unclear.
To identify changes in gene expression that may underlie V3 induced
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elastogenesis, we employed DNA microarray expression analysis to quantify
shifts in mRNA levels in V3 transduced and control ASMCs.
Primary rat vascular smooth muscle cells (VSMCs), passage 8-12, were
transduced with lentiviral vector containing versican (V3) variant or control
(empty vector) in the laboratory of Dr. Thomas Wight (Benaroya Research
Institute at Virginia Mason, Seattle, WA). Of the six sets or pair of transductions,
four pairs were cultured and harvested at the same time. One pair was from the
same transduction but cultured at an earlier date. Another sample pair was from
a different harvest of primary rat VSMCs and from a different transduction. All six
sample pairs were grown for 15-21 days and the process of RNA extraction
begun by the SolutionD method at the laboratory of Dr. Thomas Wight. The
samples were then sent to Dr. Argraves lab for further RNA processing using
RNeasy Plus Mini Kit (Qiagen) and integrity and concentration determined with a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).

4.2.4.2 DNA Microarray of V3-transduced VSMCs
Messenger RNA (mRNA) for all sets of V3-transduced VSMCs and empty
vector-transduced VSMCs were reverse transcribed at the same time, to control
for RT variations. Synthesis of biotin-labeled cRNA targets were made from the
mRNA and hybridized onto Affymetrix rat GeneChips, RAE230A. Data was
normalized by the Robust Multichip Average (RMA) method using Affymetrix
Expression Console software. A gene was considered “present” if at least three
of six controls or three of six V3-transduced samples had non-absent calls (P or
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M). Statistical analysis using a paired Student’s T test was performed for each
gene probe to comparing the samples pairs each containing a control and
experimental sample. A gene was considered statistically significant if it was
“present” and p < 0.05. Additional analysis of the effects of V3 expression on
VSMCs included a parameter to measure the ratio of average V3-transduced
VSMCs gene expression vs. average empty vector-transduced VSMCs gene
expression. Significance was set at a fold change of at least ±1.5 (at least 50%
difference in expression levels).
An alternate approach to data analysis opted to average the normalized
intensities from the 4 sample pairs cultured and harvested at the same time so as
to treat the 4 samples as 1 sample pair. Subsequent statistical analysis was
performed on the 3 sample pairs with a paired Students T-test across a gene
probe and deemed significant if p<0.05 for a gene.

4.2.5 Convergent Analysis of Microarray Datasets
Information from the five DNA microarrays studies in which elastogenesis
is a key component are summarized below including the most appropriate
statistical analysis method for the given data to identify genes significantly
regulated in each process (Table 4.1). Because the individual analyses were
performed on various DNA microarray chips and identified by Probe Set IDs
specific to their respective chip, a common ID for genes was needed to compare
data from different microarrays. All Probe Set IDs from various chips were
converted to gene symbols and re-identified as Mouse Genome 430 2.0 Probe
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Table 4.1. Microarray datasets in which elastogenesis is a key component used in
the convergent analysis.

1

, Affymetrix MG_U74Bv2 chips
, Affymetrix RAE230A chips
3
, Applied Microarrays Codelink 20K Mouse Bioarrays
4
, Affymetrix MG430v2.0 chips
E, embryonic day; P, postnatal; MUSC, Medical University of South Carolina; FDR, false
discovery rate; StDev, standard deviation; NCBI GEO, National Center for Biotechnology
Information Gene Expression Omnibus; ANOVA, analysis of variance
2

Set IDs using the Affymetrix NetAffx conversion tool. Using DChip microarray
analysis software, the five gene sets were converged to determine the
differentially regulated genes common to the 5 datasets. Heat maps for this set
were created using GeneMesh to graphically represent expression patterns.

4.2.6 Microarray Validation of Gene Expression with Quantitative RT-PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to
confirm expression changes observed in the microarray analysis. First-strand
cDNA was prepared from total RNA (1 µg) using the iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA) according to the manufacturer's specifications. cDNA
preparations were diluted 1:10, and 3 µL was used in 10-µl reactions.
73

The elastin gene was targeted with the TaqMan Gene Expression Assays
(Applied Biosystems/Life Technologies, Grand Island, NY) containing primers for
mouse/rat tropoelastin and a probe spanning the tropoelastin exon boundary 3637. Other primers designed by Primer3 and NCBI Blast for genes identified by
DNA microarray expression profiling to be regulated by microarray analysis were
used in 10 µL reactions with the iQ SYBR green Supermix reagent (Bio-Rad,
Hercules, CA).
Reactions were amplified in an iCycler real-time PCR detection system
(Bio-Rad, Hercules, CA). The resulting data were analyzed with the PCR Miner
software, which calculates individual threshold cycle values and gene efficiency
for a set of primers. All gene expression levels were normalized to a
housekeeping gene that is constitutively expressed at a relatively constant level
across many or all known conditions. (e.g., βactin, GAPDH, and TATA-box
binding protein) expression levels.

4.2.7 DNA-Chip Analyzer (dChip)
DNA-Chip Analyzer (dChip) (www.dchip.org) is a Windows software
package for probe-level (e.g. Affymetrix platform) and high-level analysis of gene
expression microarrays and SNP microarrays (211, 212). Gene expression or
SNP data from various microarray platforms can also be analyzed by importing
as an external dataset. dChip displays normalized probes from CEL files and can
pool information across multiple arrays and automatic probe selection to handle
cross-hybridization and image. Many high-level analyses are available in dChip,
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but for our studies we utilized sample comparison, hierarchical clustering, SNP
data visualization along the chromosome, and linkage analysis. In these
functions the gene and sample information are correlated with the analysis
results.

4.2.8 GeneMeSH
Another microarray analysis tool integrates categories available in the
Medical Subject Headings (MeSH) hierarchical index with a given query set of
genes. Additional tools are embedded as links to Entrez Gene information, Gene
Ontology information, KEGG metabolic pathway diagrams, and intermolecular
interaction information. An important visualization tool generates heat maps of Zscore normalized expression intensity values organized into MeSH clusters

Figure 4.2. Transcriptomic profiling of differentially regulated genes in normal
development reveals 502 unique genes. This group of genes known to regulate
elastogenesis (i.e., elastin). There are likely genes not yet identified as regulating
elastogenesis as well as genes incidental to elastic fiber assembly and common to
development. A represents a schematic of convergent analysis to identify 502 genes common
to the “developmental set” and B graphically depicts the heatmap of differential gene
expression. There are many similar expression patters in the set.
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(213). GeneMesh makes use of the heatmap.2 function in the R gplots package
and probe pair annotations available through Bioconductor (214). GeneMeSH
operates on gene expression data derived from microarray platforms Affymetrix,
Agilent, and Illumina

4.3 Results
4.3.1 Transcriptomic Profiling of Developing Elastic Tissues
Convergent analysis of the developing mouse lung and developing mouse
aorta revealed a common “developmental set” of 502 unique genes significantly
regulated (Figure 1). Many of the genes have previously been associated with
elastogenesis, while many may represent regulatory genes yet to be implicated
in elastogenesis. It is unlikely that all 502 are involved in elastogenesis and may
be an artifact of genes commonly regulated in development.

4.3.2 Transcriptomic Profiling of V3-transduced VSMCs

Analysis

of

DNA

microarray expression profiling data revealed that V3 significantly regulated
expression of 783 genes (1090 probes) (Figure 1).
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V3 up-regulated the expression of
elastin (Eln) (3.3 fold) as well as a
number of genes previously shown to
be critical for elastogenesis including
fibulin-5 (Fbln5) (7 fold), fibulin-2
(Fbln2) (2 fold), and neuraminidase
(Neu1) (8.7 fold). Several other genes
known to promote elastogenesis were
down-regulated in V3 transduced
ASMCs including transforming growth
Figure 4.3. Heatmap displaying
significantly regulated genes in
response to Versican V3 expression in
vascular smooth muscle cells (VSMCs).
1090 differentially expressed probes (783
individual genes) in aortic smooth muscle
cells transduced to express versican V3
variant or with empty viral vector (Control).
Fold change ≥1.5, p-value<0.05.

factor beta 1 (Tgfb1) (-1.5 fold) and
microfibrillar

associated

(Mfap5/Magp-2)
change

was

(-2.4
detected

protein

5

fold).

No

in

the

expression of transcripts encoding a number elastin-related genes including lysyl
oxidase (Lox), Lox-like protein (Loxl), Loxl2, fibulin-3, fibulin-4, fibrillin-1, fibrillin2, Magp1, Mfap1, Ltpb4, emilin-1 and Igf-1. Together, these data demonstrate
that versican V3 induces significant changes in mRNA expression of genes
associated with elastogenesis.
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4.3.3 Determination of the Elastogenic Gene Set
The process used to analyze the data from each microarray study and to
combine the data from the five studies is summarized in Figure 4.5. Individual
gene probes were determined to be significantly regulated within individual DNA
microarray datasets as described previously in Table 4.1. Each of the five lists of
gene probe ids were converted first to gene symbols and then converted into lists
of all possible Mouse Genome 430 2.0 Probe Set IDs for those genes using the
Affymetrix NetAffx conversion tool. Using DChip microarray analysis software,
the intersections of the five gene sets were found as depicted in the Venn
Diagram (Figure 4.5). Heat maps were created using DChip to examine their
expression patterns over time.

4.3.4 Subsets of
Elastogenic Gene
Set
The
convergent set of
commonly
regulated genes in
the

elastogenic

gene set showed
some similarities in
the

hierarchical

Figure 4.5. Convergent Venn diagram of differentially
expressed gene sets in five processes containing
elastogenesis to yield a 63-gene elastogenic gene set. The Venn
diagram illustrates the intersection of five individual microarray
analyses in which elastogenesis is a key component to yield 63
unique candidate elastogenic genes. The 63 genes within the
“elastogenic gene set” are differentially regulated in all five
processes as determined by statistical analysis specific to each
process.
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Figure 4.6. Expression patterns of the 63 candidate elastogenic genes. Convergent
analysis revealed 63 genes commonly regulated genes in five processes in which
elastogenesis is a key component.

clustering, however consistent expression patterns were not maintained
throughout the injury models and the in vitro model. Because elastogenesis is
prominent in fetal and postnatal development, developmental elastin fibers are
the gold standard by which tissue engineered elastin fibers are compared. The
expression patterns of the 63 elastogenic gene set in developing elastic tissues
was used as the basis for subsequent categorization of the 63 candidate
elastogenic genes into subsets for further analysis.

4.3.4.1 Heatmap of Developing Elastic Tissues
The expression patterns of the 63 elastogenic gene set in developing
elastic tissues was used to create a subset of potential enhancers and potential
inhibitors of elastogenesis. The heatmap was generated using dChip that
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organized genes into a specific order by a hierarchical clustering algorithm (215)
by using an average linkage method (216). The resultant heatmap depicted a
clear distinction of two groups of similarly regulated genes as indicated at the
horizontal green line (Figure 4.7).
The elastin gene was found in the top group along with other genes
expressed at high levels in adult tissue. In the early lung and aortic development
elastin is expressed at undetectable to low levels. As development progresses,
elastin expression increases to a peak during the height of elastic fiber formation
(10-14 days), and then returns to baseline levels in the adult tissue. Genes that
followed a similar pattern of low to undetectable expression in both the early
embryo and late adult with a peak of increased expression around day 10-14
were considered to behave in a similar expression pattern as elastin. Other
genes

known

to

enhance elastogenesis
(Neu1,

Fbln5)

also

follow this pattern. The
group of 29 genes of the
63

“elastogenic

gene

set” were categorized
into

a

subset

of

“potential enhancers” of
elastogenesis.
bottom

group

The
of

34

Figure 4.7. Heat map of potential enhancers and inhibitors
of elastogenesis in the “elastogenic gene set.” The
graphical representation of the expression intensity values of
the “elastogenic gene set” in the developing processes shows
two distinct groups of similarly regulated genes
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genes follows

Table 4.2. Criteria to Determine Subsets of the Elastogenic Gene Set

an expression

Average Intensity Values
Equation

pattern

Similar to
Elastin

different from
with

lower
expression
levels

during

development

Processes in which
elastogenesis is a
Processes

elastin

Different from
Elastin

Lung
Day 10 & 14 > Day 10 & 14 <
Adult
Adult
Develop- Development
ment:
Aorta
Day 7-14 > Day Day 7-14 < Day
Development
30-6 mo
30-6 mo
Day 2-3 >
Day 2-3 <
Lung Injury
Unwounded
Unwounded
Injury:
Day 5-10 >
Day 5-10 <
Skin Injury
Unwounded
Unwounded
V3-Transduced
VSMCs

V3-transduced V3-transduced
> Control vector < Control vector
transduced
transduced

and higher expression levels during adult. These genes were categorized into a
subset of “potential inhibitors” of elastogenesis.

4.3.4.2 Subsets of Elastogenic Gene Set from Computational Analysis
The criteria employed on intensity values from microarray datasets in
which elastogenesis is a key component to determine whether the gene probe of
interest behaves in a similar or different manner as elastin is presented in Table
4.2. The raw intensity values from each gene probe of the 63 candidate elastin
regulatory genes was subjected to the criteria above. If a gene probe does not
meet the criteria for behaving similar to elastin then it is determined to behave
different from elastin. In order for a gene probe to be categorized as having an
expression pattern similar to elastin during the process of Development, it must
meet the criteria for a similar expression pattern as elastin for both Lung
Development and Aortic Development. Conversely, a gene probe must not meet
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the criteria in both Lung Injury and Skin Injury to be categorized as having a
different expression pattern as elastin during the Injury Process. These criteria
provided the basis for hierarchal classification of genes as depicted in Appendix
A.
The hierarchical analysis of the 63 genes identified in the convergent
microarray analysis classified genes into groups based upon how similar or
different its expression pattern was to the elastin gene’s expression pattern in all
five processes in which elastogenesis is a key component (Appendix A). The list
of 63 genes was further subdivided based on expression patterns during
development, the period at which native elastic fiber formation occurs. Table 4.3
Table 4.3. Similar/Different Subset of Candidate Elastogenic Genes

A

B
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identifies the genes that behave

A

similar to elastin expression in
the

process

of

Development

B

(both Lung Development and
Aorta

Development)

as

determined by the equations in
Table 4.2.

The genes that

behave different from elastin
expression during Development
are

listed

in

Table

4.2B.

Subsequent promoter analysis
was

performed

these subsets.

based

upon

Figure 4.8. Validation of microarray elastin
expression in developing mouse lung.
A, The DNA microarray expression profile of relative
elastin in mouse lung development correlates with
qRT-PCR validation of developing mouse lung
cDNA in B. The expression profile demonstrates a
rise in elastin expression up to its peak around day
14 and no measurable expression in the adult lung.

4.3.5 Validation of Genes Identified in Microarray Analysis
Validation of elastin expression
in microarray analysis was performed
with cDNA from developing mouse
lung.

Figure

4.8

illustrates

the

expression profile depicting a peak
Figure 4.9. qRT-PCR validation of genes
significantly regulated in V3-transduced
VSMCs. Bars represent the ratio of gene
expression in Versican V3-transduced
vascular smooth muscle cells (VSMCs)
compared to empty vector-transduced
VSMCs (control).

elastin expression at day 14 and no
measurable expression in the adult
lung.
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Table 4.4. qRT-PCR Validation of Genes Expressed in V3-Induced VSMCs

Additional qRT-PCR was performed on cDNA from V3-transduced VSMCs
and empty vector-transduced VSMCs using primers generated by Primer3 for
genes identified as significantly regulated in the microarray dataset of V3transduced VSMCs. The fold change of V3-transduce VSMCs vs. empty vectortransduced VSMCs calculated from qRT-PCR validation can be can be seen in
Figure 4.9. Table 4.4
compares of the fold

Table 4.5. 63 genes can be placed into statistically
significant functional categories. Highlighted genes are known
to e involved with elastic fiber formation.

change of expression
from qRT-PCR to the
fold

change

calculated from DNA
microarray
expression
intensities.
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4.3.6 Functional Analysis of Convergent Genes using Gene Ontology.
Convergent analysis produced 63 genes that represent “candidate
elastogenic genes.” Among these 63 were genes well established to effect
elastogenesis, including tropoelastin, Lox, Mfap2 and Mfap5. Ontological
analysis of the 63 genes revealed that the functional categories with highest
significance were the “extracellular matrix” category (p=1.20E-05) and the
“secreted protein” category (p=6.60E-05) (Table 4.5A). In addition to the elastinrelated genes mentioned above, the ECM gene set included genes encoding
Timp2, Timp3, laminin β2, ColVα1, ColVα2 and ColXIVα1 (Table 4.5B). The
mechanism of elastic fiber formation may involve multiple signaling pathways that
may not be normally activated due to the particular injury. It is also possible that
not all genes involved in elastogenesis may be regulated on a transcriptional
level.

4.4 Discussion
Microarray analysis was performed on five different processes in which
elastogenesis was a key component. Two processes occur in elastin-rich tissues
during the period of development, the gold standard of elastic fiber quality that
tissue engineering applications strive to replicate. In order to distinguish
commonly regulated genes involved in elastogenesis from genes specific to
tissue development the DNA microarray analysis was expanded to include
models of adult elastogenesis in response to an injury of an elastin-rich tissue.
And finally, an in vitro model of a specific cell type was incorporated to
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distinguish genes regulating elastogenesis from genes that are regulated in
coordination of complex biological processes in an animal model. Five microarray
sets were selected in which active elastin transcription had occurred over a
length of time: 1) Developing lung, 2) Developing aorta, 3) Lung wound healing,
4) Skin wound healing, and 5) Versican V3-transduced vascular smooth muscle
cells (VSMCs). Each dataset was analyzed for significantly regulated genes and
through the used of dChip, convergent analysis of the five microarray datasets in
which elastogenesis is a key component yielded a common set of 63 candidate
elastogenic genes.
The list of 63 genes was further classified using gene ontology to be
significantly enriched in extracellular matrix (ECM) genes. Elastic fiber assembly
occurs at the cell surface within the ECM and mature elastic fibers reside within
the ECM to play a role in mechanical motion and cellular signaling so it would
follow that potential gene regulators in the 63-gene candidate gene set would be
enriched in the ECM ontology. Coordinately the gene ontological function of
secretion would match potential gene regulators of elastic fiber assembly and
ECM signaling.
Further investigation into significant ontological processes indicates
enrichment for oxidoreductase. This group comprises a set of enzymes that
catalyze oxidation-reduction reactions that may prove to be a hindrance to
elastogenesis. It is possible that oxidative and nitrosative modification of
tropoelastin within the in vitro model are preventing elastic fiber assembly (28). In
a study by Akhtar et al. oxidation reduced crosslinking and interactions with other
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proteins required for elastic fiber assembly, including fibulin-4, fibulin-5, and
fibrillin-2. Measurement of exogenously added oxidized tropoelastin showed less
incorporation into the preexisting microfibrils of human retinal pigmented
epithelial ARPE-19 cells compared to unoxidized tropoelastin as detected by
immunofluorescence microscopy (28). Nitration of TE was confirmed using the
rabbit anti-N-Tyr antibody, followed by a FITC-conjugated anti-rabbit secondary
antibody (28). If the in vitro culture model for the elastin ELISA is undergoing any
oxidative stress, it would follow that elastic fiber assembly may be impaired.

4.5 Conclusion
DNA microarray technology allowed for the use of high-throughput
quantification of the concurrent expression of thousands of genes. Analysis of
DNA microarray processes in which elastogenesis is a key component combined
five processes to determine commonly regulated genes for elastic fiber formation
and to distinguish those genes from coordinately regulated gene networks
specific to a biological process or tissue. All five processes occurred in elastin
rich tissues or cells and displayed an upregulation of the elastin gene. A
convergent list of 63 differentially expressed genes was gleamed from the five
processes: 1) Developing lung, 2) Developing aorta, 3) Lung wound healing, 4)
Skin wound healing, and 5) Versican V3-transduced vascular smooth muscle
cells (VSMCs).
Gene ontological analysis highlighted functional categories of extracellular
matrix (ECM) and secretion, which follow the elastin gene beginning with
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secretion of a tropoelastin monomer and subsequent assimilation into mature
elastic fibers comprising the ECM. The enrichment for the ontological group of
oxidoreductase enzymes may prove to be a hindrance to elastogenesis as
oxidation of tropoelastin prevents proper elastic fiber assembly. This may pertain
primarily to the elastogenic processes of wound healing that are undergoing
oxidative stress and ultimate assembly of inferior elastic fibers compared to
developmental elastic fibers.
The process of combining similar DNA microarray processes containing a
shared element of elastic fiber assembly provides insight into novel gene
regulatory networks involved in elastogenesis. Comparison within sets may also
elucidate differences in elastic fiber quality among different processes. The
information gained offers an unprecedented opportunity to fully characterize
elastogenesis.
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CHAPTER FIVE
TRANSCRIPTIONAL REGULATORY NETWORK ANALYSIS TO DETERMINE
CANDIDATE GENE REGULATORY NETWORKS

5.1 Introduction
DNA microarray technology allows the simultaneous measurement of the
expression of many thousands of genes. The challenge to analyzing vast
datasets to characterize biological processes relies on tools for the efficient
integration and interpretation of large datasets. Analysis of gene regulation can
be expanded to include computational tools to combine other databases with
known information on gene regulation.
One such computational tool, pathway analysis, involves looking for
consistent but subtle changes in gene expression by incorporating either
pathway or functional annotations. Pathway analysis is a promising tool to
identify the mechanisms that underlie diseases, adaptive physiological
compensatory responses and new avenues for investigation (217).
Other computational tools integrate functional genomics data, for example,
from microarray-based gene-expression analysis with genomic sequence data to
carry out transcriptional regulatory network analysis (TRNA) (218). TRNA
combines bioinformatics to identify and analyze regulatory regions of genes with
statistical significance testing to determine the likelihood of the binding of
transcription factors (TF). We further refined our set of candidate elastogenic
genes with TRNA to identify potential regulatory pathways for elastogenesis.
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5.1.1 Gene Regulation
An organism is comprised of many different tissues that perform a wide
range of functions yet the entire genome encoding these functions is found in
every cell within the organism. This phenomenon is due to a process known as
gene regulation, whereby only a fraction of genes in the genome are expressed
in a given cell. Gene regulation occurs throughout the entirety of gene expression
from chromatin organization, transcription, pre-mRNA processing, translation,
and post-translational modifications but chiefly at the transcriptional level (219).
Transcription involves the conversion of the genetic code comprised of
deoxyribonucleic acid (DNA) into messenger RNA (mRNA), which can then serve
as a template for protein synthesis. The biological mechanism of transcription is
regulated by an extensive network of proteins known as transcription factors
(TFs) that bind to a complementary DNA sequence binding sites or
transcriptional regulatory elements (TREs). The TREs are primarily located in the
cis-regulatory region (promoter) of a gene approximately 100-1000 base pairs
upstream (towards the 3’ region of the anti-sense strand, or non-coding strand)
(220), however some TREs have been found from 200bp downstream of the
origin of replication (ORI), up to tens of thousands of bp upstream (219). When a
TF binds to a corresponding TRE the level of transcription of the downstream
gene can be initiated, stopped, up or down-regulated. Figure 5.2 shows the
interaction of TFs/TREs with the promoter of a gene to regulate transcription.
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5.1.2

Gene

Regulatory
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Figure 5.1. Gene Regulation. Transcription factors (TFs)
bind to corresponding transcriptional regulatory elements
(TREs) .The TFs/TREs interact with the promoter region
upstream to the start of transcription to initiate, stop, up or
down-regulate the level of transcription of the downstream
gene.

processes such as development, differentiation, proliferation, cell cycle, and
extracellular matrix organization.

Transcription factors (TFs) serve as an

important component of this network, responding to changes in the cellular
environment by altering the gene expression of relevant genes (221). TFs
specifically bind to a corresponding sequence of a TRE however TREs are not
specific to a single gene. Multiple genes have the same TREs present resulting
in an interconnected transcriptional regulatory network where TFs bind and
regulate many different genes.
Understanding the complexity of these gene regulatory networks relies on
the compilation of technological developments such as gene expression changes
from microarrays, protein–DNA interaction and transcription factor activity data
from protein binding assays, chromatin immunoprecipitation (ChIP) experiments
(222), and DNA footprinting (223, 224), protein–protein interactions from two
hybrid experiments and coimmunoprecipitation, and genomic sequence and
ontology information in public databases (www.geneontology.org) (220). By

91

analyzing data from multiple sources of regulatory assays, we may achieve a
better understanding of the dynamic systems of the gene regulatory network.

5.2 Materials and Methods
5.2.1 Promoter Analysis Technology
The binding of TFs to TREs is the crux of the biological mechanism of
transcriptional regulation. Because these reactions are sequence specific,
bioinformatics tools are able to access available databases containing annotated
sequences for gene sequences and cross-compare databases of annotated
TREs. By scanning the genome for sequence recognition, new technology is able
to identify the presence of a TRE in the promoter region of a gene thus predicting
the possibility of TF-TRE binding.
Many studies have taken this direct approach to promoter analysis to
identify a good candidate set of network interactions (225-227). Promoter
analysis has been utilized most successfully in yeast to develop sets of
coregulated genes (67) and detailed gene regulatory networks for the galactoseutilization pathway (68). Promoter analysis can also be used to identify genomic
regions containing unusually high concentrations of predicted TREs. One study
in the developing Drosophila embryos identified enriched genomic regions for
five active TFs of interest (228). Gene regulatory networks are also at play during
development in to regulate cell fate in the embryo of sea urchins to control the
specification of endoderm and mesoderm (229). The first study to employ
promoter analysis to identify regulatory gene networks in higher order species
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focused on transcriptional mechanisms that control cell cycle progression in
humans (230). By analyzing the promoters in a set of genes whose expression is
cell-cycle-dependent, Bury identified a set of 8 transcriptional factors whose
binding sites were overrepresented.
Promoter analysis is able to identify transcription factor (TF) binding
regions within the genetic code and thus predict binding of TFs that regulate
gene expression. Through analysis of the promoter regions of the candidate
elastogenic gene set, we analyzed the TF-binding site occurrences for
over/under

representation

within

our

63

candidate

elastogenic

genes.

Transcriptional regulatory network analysis (TRNA) combines pathway analysis
and statistical significance testing to identify potential transcription factor
regulators of elastogenesis.

5.2.2 PAINT: Promoter Analysis and Interaction Network Generation Tool
The Daniel Baugh Institute for Functional Genomics/Computational
Biology at Thomas Jefferson University developed a bioinformatics tool PAINT:
Promoter Analysis and Interaction Network Generation Tool to automate the
analysis of a given set of genes to produce an interaction matrix that represents
a candidate set of interactions between the transcription factors and the genes.
PAINT is able to identify potential regulatory networks given an input set of
genes of interest. PAINT processes a list of unique identifiers representing the
genes of interest by referencing the database UpstreamDB to identify 5000 bp
upstream and 100 bp downstream of a gene. This process is not organism-
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specific as the key requirements are the availability of an annotated genome
sequence. UpstreamDB was constructed for all the known and putative
annotated genes in the Ensembl genome database for Mus musculus. This
promoter sequence database is periodically updated by PromoterID/DBSync,
which also serves to identify the transcription start site. The TFRetriever module
makes use various transcription factor inspection/discover programs that can
retrieve and process the sequences for TREs of known TFs. The unique gene
sequences are processed by the FeasNet Builder component that produces a
Candidate Interaction Matrix (CIM) for the genes of interest. Statistics are also
generated within this module to compare the over-representation of the TREs in
the set of given promoters with respect to a background set of promoters. The pvalues are calculated using hypergeometric distribution (230-232) to give the
probability that the observed counts for the TREs in the set of promoters could be
explained by random occurrence in the reference set of promoters. The final
PAINT component FeasNetBuilder constructs an interaction matrix representing
a candidate set of connections in the regulatory network with the input genes of
interest organized into rows and the columns corresponding to the TREs. The
regulation of a gene is represented by the color of the box at the intersection of a
row and column: red if a TRE was identified as over-represented in that gene’s
promoter, blue for under-representation, and black otherwise. The lower p-value
(0 < p < 0.01) indicating a higher degree of significance for a particular TRE in a
CIM are indicated in a brighter/lighter shade of red for over-representation or
cyan for under-representation (220). The organization of the PAINT modules
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from the input gene list to the visualization of a candidate regulatory network can
be seen in Figure 5.1. In summary, the bioinformatics tool PAINT is able to
process a given set of genes to generate a pruned list of transcription factors that
are ranked on the likelihood
of

the

resultant

involvement.
data

can

The
be

examined in detail in further
experimental

studies

on

gene regulation (220).
In order to identify
potential

transcriptional

regulators of elastogenesis
in the 63 gene “elastogenic
gene set” the bioinformatics

Figure 5.1. Flow of Data through the Bioinformatics
Tool PAINT. The input and intermediate outputs are
organized on the left. The five core components of
PAINT are boxed in: UpstreamDB, PromoterID/DBsync,
TFRetriever, FeasNetBuilder, FeasNet Viewer. Dashoutlined boxes represent external databases and
programs utilized by PAINT.

tool PAINT (218, 220) was
used to analyze the promoter sequences. Optimal parameters and input gene
sets were determined with the assistance of Dr. Jeremy Barth in the COBRE
Proteogenomics Facility at the Medical University of South Carolina. Because
developmental elastogenesis is considered the gold standard for elastic fiber
quality, PAINT analysis was performed on the “elastogenic gene set” subsets of
“potential enhancers” and “potential inhibitors” derived from the microarray
datasets from developing lung and developing aorta described in 4.3.1.
Transcriptional regulatory elements (TREs) were identified as being significantly
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overrepresented in the promoters of the enhancer or inhibitor subset with respect
to a background set of promoters (p<0.05). Dr. Barth was able to access the
TRANSFAC Pro licensed database to find TREs and he suggested analyzing a
promoter region limited to 2000 bp upstream of the transcription start site and a
False Discovery Rate (FDR) < 0.10.

5.2.3. UCSC Genome Browser
Transcription factor analysis using PAINT indicates the presence of a
transcription factor (TF) binding sites (TREs) within the given parameter of base
pairs designated during the search described previously. Resultant displays
indicate the presence of a TRE but not the specific location. The University of
California at Santa Cruz (UCSC) Genome Browser provides a way to examine
genomic data and map specific TF binding sites. UCSC Genome browser can
also include extensive annotation tracks for various data types including known
chromatin immunoprecipitation (ChIP) datasets. The ENCODE function links to
downloadable tracks and files corresponding to searchable terms. We
downloaded BroadPeak ENCODE files for transcription factors regulated in
PAINT analysis.

5.2.4 MicroRNA Analysis of Elastogenic Gene Set
MicroRNAs (miRNAs) are short, single-stranded RNAs that bind to
messenger RNA (mRNA) to regulate gene expression, usually by blocking
translation. A wide range of biological processes involve miRNA-mediated
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regulation as a key component such as developmental timing, metabolism,
apoptosis, cardiac and skeletal muscle proliferation (233) and neuronal gene
expression (234). Changes in expression, copy number or mutations of miRNA
can lead to diseases in humans including cancer. MicroRNA expression is
prevalent in almost all cell types and conserved among most species suggesting
miRNAs are vital to biological processes.
Recent studies show that expression of the microRNA, miR-29, is reduced
by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR-29 (130,
131). Furthermore, miR-29 mimics decrease elastin mRNA levels in dermal
fibroblasts and vascular smooth muscle cells (132). Moreover, in the developing
mouse aorta, an up regulation in the expression of miR-29 as well as several
other microRNAs that have targets in the elastin mRNA (i.e., the miR-15 family
members miR-195 and miR-497) accompanies the down regulation of elastin
mRNA in the period between the newborn and adult (130, 131).
Numerous resources exist predicting miRNA binding based on sequence
complementarity. One such tool is microRNA.org, a resource for microRNA
target predictions and microRNA expression that uses the miRanda algorithm
that computes optimal sequence complementarity between a set of mature
microRNAs and a given mRNA using a weighted dynamic programming
algorithm (235). The microRNA expression profiles were taken from a recent
profiling study across ∼250 small RNA libraries collected from human, mouse
and rat tissues and cell lines (236).
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Target mRNA searches were performed on each of the 63 genes in the
candidate elastogenic gene set. All isoforms of miRNAs were collected for the
mouse genome and organized based on number of occurrences. Additionally,
genes were sorted based upon number of miRNA.

5.3 Results
5.3.1 Defining Candidate Regulatory Interactions
Transcriptional regulatory network analysis revealed potential transcription
factor (TF) regulators of the subsets of the candidate elastogenic genes as

Figure 5.2. Transcription factor binding regions are predicted potential enhancers and
potential inhibitors of elastogenesis. The remaining transcription factors have not been
associated with regulating elastin or elastogenesis to date. We’re interested to determine
whether they represent novel regulatory factors in the process of elastogenesis. Several of
these have pharmacological antagonists and agonists that can be tested to see if they exert
effects on elastogenesis.
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determined by dChip heatmap categorization. Among the genes whose
expression pattern is similar to elastin, eleven TREs were significantly enriched.
Importantly, four of the eleven transcription factors (TFs) binding to the TREs, BMyb Sp1, cKrox and PPAR, have been previously implicated in elastogenesis
(146, 237-239). For example, studies have shown that B-Myb represses
expression of elastin in VSMCs (237) and lysyl oxidase (Lox) expression in
fibroblasts (240). cKrox also repress elastin expression in fibroblasts (36), while
Sp1 stimulates elastin expression in fibroblasts (147). PPAR has dual effects on
elastin transcription: both increasing (241) and repressing elastin expression in
fibroblasts (238, 242). To
date, these regulators have
not been targeted in tissue
engineering approaches.

5.3.2 TREs identified within
the Elastin Promoter
PAINT
determined

analysis
five

DNA

sequences corresponding to
TREs to be significantly
overrepresented within the
elastin

promoter

region

analyzed (Figure 5.3). Two

Figure 5.3. PAINT analysis determined five DNA
sequences corresponding to TREs to be significantly
overrepresented within the elastin promoter region
analyzed. Two of the five TREs are known to regulate
elastin: PPAR and Sp1. The other three TREs have not
be associated with elastin to date: WT1, ZF5, and Ckrox.
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of the five TREs are known to regulate elastin: PPAR and Sp1 while the
remaining three TREs have not be associated with elastin to date: WT1, ZF5,
and Ckrox. Given that 2 of the 5 TREs identified on the elastin promoter through
the PAINT analysis have already been demonstrated to regulate elastin
transcription, the use of promoter analysis technology is validated to predict
candidate regulatory interactions. It would follow that the WT1, ZF5, and Ckrox in
the elastin promoter are worth investigating, along with other TREs regulating the
genes which are regulated similar to elastin during development.

5.3.3 UCSC Genome Browser Mapping of Transcription Factor Binding Sites
Previous chromatin immunoprecipitation (ChIP) studies using PPARα chip
were uploaded to the USCS Genome Browser in the form of broadPeak tracks.
Using the UCSC Genome Browser and the ENCODE search function to align

Figure 5.4. Transcription factor binding sites for p300, a PPAR coactivator, are located
close to the transcription start site of the human elastin gene. The UCSC Genome
Browser allowed visualization of transcription factor binding sites along the elastin gene as
compiled from multiple chromatin immunoprecipitation (ChIP) studies.
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tracks from PPAR ChIP studies, we located a PPARα transcription factor binding
site closest to the start site of elastin transcription approximately 50 kilobasepairs
(kbp) upstream. Expansion of the elastin gene in the UCSC Genome Browser
also demonstrates multiple binding sites for the PPAR coactivator p300 (243)
(Figure 5.4).
Previous

chromatin

immunoprecipitation

(ChIP)

studies

indicate

transcription factor binding sites close to the transcription start site of the elastin
gene as seen in Figure 5.5. Two binding sites interchangeable for transcription
factors WT1 and EGR-1 are located upstream of the transcription start site within
the elastin promoter
(<

5

kbp)

and

downstream of the
Figure 5.5. Previous chromatin immunoprecipitation (ChIP)
studies indicate 2 EGR-1/WT1 Binding Sites within 5kb from
the human elastin gene transcription start site.

transcription

start

site (< 2.5 kbp).

5.3 4 MicroRNAs Common to Elastogenic Gene Set
MicroRNA analysis of candidate elastogenic gene set identified 177
different miRNAs known to regulate the 63 genes commonly regulated in all five
elastogenic processes, of which 112 miRNAs have at least 5 binding sites within
the set, and 31 miRNAs bind at least 10 sites. Table 5.2 is organized horizontally
by miRNAs in decreasing number of total miRNA binding sites and organized
vertically in ascending order from genes with the most number of miRNA binding
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sites down to the least regulated genes. The most represented miRNA is miR200 with 31 binding sites in 16 different genes, followed by miR-181 with 28
binding sites in 7 different genes, and miR-29 with 27 binding sites in 9 different
genes. The gene regulated by the most binding sites for miRNA is Hnrnpa2b1
with 53 miRNA binding sites for 43 different miRNAs, followed by Marcks with 43
miRNA binding sites for 34 different RNAs, and lysyl oxidase (Lox) with 42
miRNA binding sites for 32 different miRNAs. The largely regulated Lox, an
important crosslinker of elastin fibers and significant presence of miR-29, a
known regulator of elastogenesis, within the 63-gene elastogenic gene set
indicate miRNAs play a likely role in the regulation of elastogenesis.
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Table 5.2. MicroRNAs Common to Elastogenic Gene Set

Only four genes of the 63 were not known to be regulated by any miRNAs
including AE binding protein 1 (Aebp1), apolipoprotein E (Apoe), and cell division
cycle 20 homolog (Cdc20), and FXYD domain-containing ion transport regulator
1 (Fxyd1).
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5.4 Discussion
Transcriptional regulatory network analysis tool PAINT utilized databases
containing sequences of gene regulatory regions and transcription factors to
detect transcription factors overrepresented in the 63 candidate elastogenic
genes. Promoter analysis was performed on the two subsets of genes as
determined by dChip heatmap categorization and a total of 28 transcription
factors were identified as potential regulators of elastogenesis. In the subset of
genes whose expression pattern is regulated similar to elastin and categorized
as potential “enhancers” of elastogenesis, eleven transcription factors were
overrepresented compared to a reference set of genes. Four of the eleven
transcription factors have been previously implicated with elastogenesis (B-Myb
Sp1, cKrox and PPAR while the remaining seven have yet to be associated with
elastogenesis. The finding of transcription factors known to regulate elastin
transcription validated this approach for finding transcriptional regulators of
elastogenesis. This finding also increases the likelihood that the 63-gene
“elastogenic gene set” group represents a true core of elastogenesis related
genes. By extension, the 11 TFs identified by this analysis may represent an
elastogenesis regulatory network.
PAINT analysis of the genes whose expression pattern is different from
elastin distinguished 17 transcription factors to be enriched, including, v-Myb,
which binds TREs in 23 of the 35 gene subset. Of importance to this set is the
transcription factor early growth response 1 (EGR-1) that binds to the same
consensus sequence as another transcription factor Wilms’ tumor 1 (WT-1) that
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was enriched in the alternate subset. Both transcription factors are members of
the family and are considered oncogenes and tumor suppressors (244).
Wilms tumor regulates the expression of multiple growth factors including
colony-stimulating factor (245), platelet-derived growth factor (246), and known
modulator of elastin transcription insulin-like growth factor I (247). A mutation
resulting in the loss of WT1 expression leads to up-regulation of these growth
factors and the formation of Wilms tumor, thus its original classification as a
tumor suppressor (248). However, subsequent studies have revealed a potential
role for WT1 as an oncogene due to its upregulation in a variety of human
cancers such as astrocytic tumors (87, 249), breast cancer (250), leukemia
(251), and sporadic Wilms tumor (252, 253), which accounts for ∼85% of all
Wilms tumors.
Both WT1 and EGR1 are members of the family of zinc finger proteins
(254) with similar structures and consensus sequences resulting in competition
for transcription factor binding sites. WT1/EGR-1 binds 5'-GCG TGG GCG-3'
(and similar ones like 5'-GCG GGG GCG-3') (255, 256). The effects of binding
are most often mutually opposing whereby EGR1 activates the transcription of
genes that WT1 represses (257, 258). Like WT1, EGR1 expression levels are
atypical in multiple neoplastic cell types such as prostate cancer (259),
glioblastoma (260), and Wilms tumor (253). Furthermore, EGR1 can also act as
either an oncogene (259) or a tumor suppressor (248-253, 257-261) in different
cell types. EGR-1 targets genes including immune effector genes, such as the
cytokine IL‐2 (262, 263), the pro‐inflammatory immune mediator TNFα (264), a
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known suppressor of elastin transcription (113) and promoter of elastin
degradation (177).
Similar structures and consensus sequences results in competition of
binding for transcriptions factors WT1 and EGR-1. Binding often results in
opposing regulation of the same gene (257, 258). The enrichment of both
transcription factors in opposing subsets of the 63-gene elastogenic gene set
validates the approach of transcriptional regulatory network analysis using PAINT
to identify regulators of elastogenesis. It is likely that WT1 and EGR-1 coordinate
the up-and down-regulation of elastogenesis.
Analysis of WT1/EGR-1 consensus sequences using the UCSC Genome
Browser and previous chromatin immunoprecipitation (ChIP) studies illustrated
two binding sites close to the start site of elastin transcription. Additional ChIP
studies indicate the binding sites for PPARα upstream of the elastin transcription
start site as well as multiple PPAR coactivator p300 binding sites in closer
proximity to the transcription start site. The findings from transcriptional
regulatory network analysis indicating enriched transcription factor binding sites
within the 63-gene elastogenic set and subsequent binding site mapping
proximal to the elastin transcription start site using ChIP studies indicate PPAR
and WT1/EGR-1 as potential regulatory transcription factors of elastogenesis.
Other important regulators of transcription include microRNAs. Although
elastin expression decreases shortly after the perinatal period and remains low in
adult tissues (265), interestingly tropoelastin premRNA levels remain elevated in
adult rat lungs despite considerably reduced steady-state mRNA levels. This
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suggests posttranscriptional regulation of mRNA may be a predominant
mechanism to regulate elastin mRNA (87).
Recent studies show that expression of the microRNA, miR-29, is reduced
by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR-29 (130,
131). Furthermore, miR-29 mimics decrease elastin mRNA levels in dermal
fibroblasts and vascular smooth muscle cells (132). Moreover, in the developing
mouse aorta, an up regulation in the expression of miR-29 as well as several
other microRNAs that have targets in the elastin mRNA (i.e., the miR-15 family
members miR-195 and miR-497) accompanies the down regulation of elastin
mRNA in the period between the newborn and adult (130, 131).
miR-29 was the third most occurring miRNA with binding sites in the
elastin (Eln), lysyl oxidase (Lox), microfibrillar associated protein 5 (Mfap5) , and
microfibrillar associated protein 2 (Mfap2) which are all known to be involved in
elastogenesis. The predominate occurrence of miR-29 binding sites within the
set of 63 candidate elastogenic genes supports the analysis of miRNA binding
sites to predict regulation of elastogenesis. miR-29 also binds to collagen type V,
alpha 2 (Col5a2), collagen type IV, alpha 5 (Col4a5), cysteine dioxygenase 1,
cytosolic (Cdo1), ectonucleotide pyrophosphatase/phosphodiesterase 2 (Enpp2),
and hexosaminidase A (Hexa) which have not previously been shown to regulate
elastin but may warrant investigation.
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5.5 Conclusion
The challenge to analyzing the copious amount of data within DNA
microarrays is selecting the appropriate computational tools to integrate genomic
and functional databases and interpret coordinately regulatory networks of
genes. Promoter Analysis and Interaction Network Generation Tool, PAINT,
utilizes a database of gene regulatory sequences located in the promoter region
upstream of the transcription start site and cross-references with a database of
know transcription factor binding sites or response elements (TREs) to predict
the likelihood of transcription factor binding in a given set of genes. Enrichment of
TREs in a given set of genes is compared to a random reference set of
promoters to ensure statistically significant overrepresentation of TREs. Analysis
of the subset of the 63-gene candidate elastogenic set in which expression
patterns were similar to elastin characterized 11 overrepresented TREs of which
four were previously known to regulate elastogenesis: B-Myb Sp1, cKrox and
PPAR. A closer look at the TREs enriched within the elastin promoter revealed
five overrepresented TREs, of which two were known form previous studies to
regulate elastin: PPAR and Sp1. The finding of elastogenic transcription factors
validates the use of PAINT to identify regulators of elastogenesis. Many new
candidate elastin regulating transcription factors were identified for which
pharmacological agents exist and can ultimately be tested for effects on
elastogenesis.
Specific mapping of TREs using chromatin immunoprecipitation (ChIP)
studies and the UCSC Genome Browser illustrated binding sites for PPAR, a
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PPAR coactivator, and WT1/EGR-1 around the elastin transcription start site.
The likelihood of TF/TRE binding in the elastin promoter indicates PPAR and
WT1/EGR-1 as potential regulators of elastogenesis.
Additional gene regulation was assessed through target mRNA searches
with microRNA.org. MicroRNA (miRNA) binding sites on the 63 genes in the
candidate elastogenic gene set were particularly prevalent in Lox, an important
crosslinker of elastin fibers. Additionally miR-29, a known regulator of
elastogenesis, was significantly predominant within the 63-gene elastogenic
gene set. It is likely that other miRNAs highlighted in the miRNA analysis play a
likely role in the regulation of elastogenesis.
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CHAPTER SIX
MODULATORS OF TROPOELASTIN EXPRESSION IN AN IN VITRO
CULTURE MODEL

6.1 Introduction
Prior studies have shown that elastin matrix synthesis is regulated by
numerous biochemical factors that may be promote elastin synthesis (Table 5.2)
or inhibit or degrade elastin (Table 5.3) as summarized previously in Chapter 3.
Convergent microarray analysis identified 63 genes as candidate regulators of
elastogenesis which can be tested in vitro through pharmacological agonist or
antagonists. Subsequent transcriptional regulatory analysis with PAINT identified
potential regulatory transcription factors that if targeted with pharmacological
agonists or antagonists may prove to regulate multiple elastogenesis regulating
genes within the set of 63 candidate regulators. In the case that agonists or
antagonists are unavailable, transfection of a plasmid expression vector
containing the genetic sequence for a gene or transcription factor of interest can
be used to upregulate expression. Conversely, transfection of small interfering
RNA (siRNA) can be used to downregulate expression.

6.2 Materials and methods
6.2.1 Cell Culture
Human foreskin fibroblasts (HFF, ATCC no. SCRC-1041) were obtained
as a generous gift from Dr. LaRue. HFFs were expanded in Dulbecco’s Modified
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Eagles Medium (DMEM) High; with Sodium Pyruvate and without L-glutamine
(Fisher Scientific) supplemented with 15% v/v FBS (Atlanta Biologicals), 1% v/v
GlutaMAX

(Life

Technologies,

Grand

Island,

NY),

and

1%

v/v

penicillin/streptomycin (Fisher Scientific). Media was changed every 3 days and
cells were passaged at 80-90% confluence with TrypLE Express (Life
Technologies, Grand Island, NY). Low passage (6-8) HFFs were used for the
following studies.
Neonatal rat aortic smooth muscle cells (nRASMCs) were isolated by a
method based on that described by Oakes et. al.(266). Three litters of neonatal
Sprague-Dawley rats (~21 rats aged 3 days postnatal) were sacrificed previously
by CO2 asphyxiation and decapitation as per protocols approved by the Animal
Research Committee at the Medical University of South Carolina and at Clemson
University. Aortal segments were removed from euthanized rats, from arch to the
celiac axis, under sterile conditions, and spliced lengthwise in petri dishes
containing cold phosphate-buffered saline (PBS) containing 2 mM Ca2+. These
spliced sections were then transferred to a dish containing 1-2 ml of collagenase
(2 mg/ml; Worthington) and incubated for 10 minutes at 37 °C. Dulbecco’s
Modified Eagles Medium (DMEM) supplemented with 15% FBS and 1% v/v
penicillin/streptomycin (Fisher Scientific) that had been passed through a 0.22
µm sterile filter was then added to these collagenase treated samples and mixed
well with gentle pipetting. Isolated aortal segments were further chopped
crosswise into 0.5 mm long pieces and transferred using fine needles onto sterile
petri dishes, pre-scratched to facilitate cell attachment. The explants were
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incubated in limited volumes of the above medium at 37 °C for a week, to
establish primary culture. Cells were periodically observed microscopically in
order to monitor attachment and proliferation. At the end of one week, the
explants were removed carefully and sufficient media added to the dish to
promote cell proliferation. After the 2nd passage, cells were proliferated in DMEM
High; with Sodium Pyruvate and without L-glutamine (Fisher Scientific)
supplemented with 10% v/v FBS (Atlanta Biologicals), 1% v/v GlutaMAX (Life
Technologies, Grand Island, NY), and 1% v/v penicillin/streptomycin (Fisher
Scientific). Media was changed every 3 days and cells were passaged at 80-90%
confluence with TrypLE Express (Life Technologies, Grand Island, NY). Low
passage nRASMCs (P4-8) were used for the following studies.

6.2.2 Immunostaining Elastin Fibers.
HFFs were cultured in DMEM previously described in 6.2.1 at a density of
1.0x104 cells/cm2 in an 8-well chamberslide. After 3, 5, 7, and 14 days of culture
cells were rinsed twice with PBS and fixed in cold methanol for 10 minutes. The
monolayer was rinsed 3 times in PBS before incubation in blocking solution of
5% goat serum in PBS for 30 minutes at room temperature (RT). Cells were then
incubated overnight at 4ºC with 1:1000 primary anti-bovine elastin antibody (a
generous gift from Dr. Mecham) in solution containing 1% goat serum in PBS.
Cells were washed 3 times with PBS before secondary antibody labeling with
Alexa Fluor 546-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat
serum in PBS for 45 minutes at RT. All unbound antibody was washed away with
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3 washes of PBS before nuclear staining with DAPI in Vectashield mounting
medium (Vector Laboratories, Burlingame, CA) and coverslipped. Elastin fibers
were detected by immunofluorescent imaging using a Leica sp5 confocal
microscope with a 20X objective.

6.2.3 Quantitative RT-PCR
RNA was extracted 24h after treatment using Qiagen’s RNeasy RNA
extraction kit according to the manufacturer’s instructions. RNA integrity was
assessed by a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA), and
cDNA was prepared using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA)
with 1 µg RNA according to the manufacturer’s instructions. 10 µL reactions of
each sample were prepared using 5 µL SSO Fast EvaGreen supermix (Bio-Rad,
Hercules, CA), 0.5 µL each 10 µM forward and reverse primers, 1 µL DEPCtreated water, and 3 µL of the optimized dilution of cDNA. Reactions were
amplified for forty cycles at optimized temperatures in an iCycler real-time PCR
detection system (Bio-Rad, Hercules, CA). The resulting data were analyzed with
the PCR Miner software, which calculates individual threshold cycle values and
gene efficiency for a set of primers. All gene expression levels were normalized
to a housekeeping gene that is constitutively expressed at a relatively constant
level across many or all known conditions. (e.g., βactin, GAPDH, and TATA-box
binding protein) expression levels.
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6.2.4 Pharmacological Agonist/Antagonist Treatment.
In order to screen candidate genes and transcription factors of interest, an
in vitro culture model was designed to test pharmacological agonists and
antagonists. Human foreskin fibroblasts (ATCC no. SCRC-1041) (HFFs) were
plated in 6-well plates at 1.0x104 cells/cm2 and allowed to attach overnight. In
some experiments cells underwent serum starvation for 18 – 24 h in DMEM High;
with Sodium Pyruvate and without L-glutamine (Fisher Scientific) supplemented
with 0.1% v/v FBS (Atlanta Biologicals), 1% v/v GlutaMAX (Life Technologies,
Grand Island, NY), and 1% v/v penicillin/streptomycin (Fisher Scientific) so as to
synchronize cell cycle phase (267) and maximize mRNA production after
treatment. Pharmacological agonists and antagonists to transcription factors
were added in fresh DMEM High; with Sodium Pyruvate and without L-glutamine
(Fisher Scientific) supplemented with 10% v/v FBS (Atlanta Biologicals), 1% v/v
GlutaMAX

(Life

Technologies,

Grand

Island,

NY),

and

1%

v/v

penicillin/streptomycin (Fisher Scientific) or fresh low serum (0.1%) media for
serum starvation experiments.
It was predicted that hypothesized positive effectors of elastogenesis (e.g.,
neuraminidase, IGF-1) would increase the total amount of elastin transcription,
deposition and/or increase the rate of elastin deposition. Conversely, negative
effectors of elastogenesis (e.g., chondroitin sulfate) would decrease the total
amount of elastin transcription, deposition and/or decrease the rate of elastin.
Sp1. Sp1 is a known regulator of elastic fiber formation (146; Sen, 2011
#165) that was implicated in the PAINT analysis as having a potential binding site
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in the elastin promoter. In order to validate the PAINT analysis and the culture
model we administered mithramycin (Sigma, St. Louis), a Sp1 antagonist, to
inhibit elastin.
PPAR. PPAR was identified through PAINT analysis as a potential
regulatory transcription factor of elastogenesis with a potential TRE located in the
elastin promoter. PPAR has already been shown to have dual effects on elastin
transcription: both increasing (241) and repressing elastin expression in
fibroblasts (238, 242). PPARα has yet to be examined for its role in
elastogenesis therefore we tested the effects of PPARα agonist and antagonist
on elastin expression.
HFFs were plated at confluence and allowed to attach overnight before
treatment with 1 – 100 µM PPARα agonist (C7081, Sigma), 3.33 – 30 µM
PPARα antagonist (GW6471, Sigma), and/or 10 – 30 µM PPARγ antagonist
(GW9662, Sigma). RNA was extracted at 24 h using Qiagen’s RNeasy RNA
extraction kit according to the manufacturer’s instructions. RNA integrity was
tested by Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA) and cDNA was
prepared using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) with 1 µg
RNA according to the manufacturer’s instructions. cDNA preparations were
diluted 1:10, and 3 µL was used in 10-µl reactions for qRT-PCR as described
previously in 6.2.3.
WT1/EGR-1. WT1 was identified as an enriched transcription factor by
PAINT in the analysis of the subset of genes whose expression pattern is similar
to elastin. A similar transcription factor that binds the same consensus sequence
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on a TRE was identified in the other subset of the candidate elastogenic gene
set. EGR-1 was enriched to bind the subset of genes with an expression pattern
different from elastin. EGR-1 has a similar conformational structure as WT1 and
often regulates the same genes in an opposing direction. The identification of
these pair of opposing transcription factors in the different subsets suggest WT1
and EGR-1 act to coordinate regulation of the elastin gene.
The one available pharmacological agent to regulate transcription factors
WT1 or EGR-1 was the WT1 antagonist Ganetespib (Sta-9090), an
investigational anticancer drug developed by Synta Pharmaceuticals (Lexington,
MA). Ganetespib is a small molecule inhibitor of heat shock protein 90 (HSP90),
a molecular chaperone required for the proper maturation and activation of
numerous client proteins and often overexpressed in cancer (268-271). Hsp90

Figure 6.1. Egr-1 is hypothesized to signal through the MAPK pathway and suppress
elastin transcription. Conversely, displacement of Egr-1 by transcription factor WT1 will
shift the signaling cascade of events toward increase elastin transcription.
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also associates with WT1 protein and stabilizes its expression (272).
Pharmacological inhibition of Hsp90 with Ganetespib resulted in ubiquitination
and subsequent proteasome-dependent degradation of WT1 in the human CML
cell line K562 and AML cell line KG-1. Downstream targets of WT1, c-Myc and
Bcl-2 were also subsequently downregulated (272).
EGR-1 was experimentally determined to be a downstream target of
extracellular signal-regulated kinase 1 and 2 (ERK1/2) in a mononuclear
phagocyte (RAW) cell culture model. Carbon monoxide mediated suppression of
ERK activation resulted in Egr-1 inhibition. ERK 1/2-driven Egr-1 expression and
regulation of its downstream target genes was cGMP-dependent (273).
Modification of the signaling cascade of factors regulating elastin transcription by
insertion of Egr-1 leads to the hypothesis that Egr-1 is a negative regulator of
elastin transcription via the MAPK pathway. Conversely, displacement of Egr-1
by transcription factor WT1 will shift the signaling cascade of events toward
increase elastin transcription. Treatment of HFFs with 12 nM – 1 µM Ganetespib
is expected to antagonize WT1 and thus decrease elastin transcription compared
to MeOH controls. If elastin regulation is mediated via the MAPK pathway, coculture of 37 nM Ganetespib with 50 nM Mek inhibitor PD98059 may reverse the
effects by decreasing downstream Egr-1 and upregulating elastin transcription.
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6.2.5 Transfection of Plasmid Expression Vectors
6.2.5.1 Plasmid Stock Culture Preparation
In the absences of pharmacological agents to augment expression of WT1
and EGR-1, transfection of plasmid expression vectors containing the sequence
for WT1 and EGR-1 were performed on HFFs. Sequence-Verified human WT1
and EGR1 were generated from the Mammalian Gen Collection (MGC), a transNIH initiative, that provides sequence-validated full-length protein-coding (FLCDS) cDNA clones (Thermo Fisher Scientific, Pittsburgh, PA). Plasmids were
obtained as live bacterial cultures containing the plasmid of interest. Stock
cultures for each plasmid were prepared by isolation of a single colony from a
streak plate on LB agar containing 100 µg/mL ampicillin. Bacterial cultures of
stock cultures for WT1 and EGR-1, in addition to empty vector control were
proliferated in 100 mL Luria Broth (LB) medium containing 100 µg/mL Ampicillin
overnight and plasmid purification performed with a Plasmid Midi Kit (Qiagen,
Valencia, CA) according to manufacturer’s instructions. Plasmids were extracted
and concentration determined by spectrophotometry. Concentrations were
adjusted to be equal for each type of plasmid.

6.2.5.2 Transfection with Amaxa Nucleofector Kit
Transfection of human foreskin fibroblasts (HFFs) with plasmid vectors
with performed with a Lonza Amaxa Nucleofector Kit (Lonza) according to
manufacturer’s protocol. For each transfection reaction 82 µL of Nucleofector
Solution plus 18 µL of supplement was combined to make 100 µL of total
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reaction volume. Passage 7 HFFs were detached from the plate with TrypLE. 3 x
106 cells/transfection were centrifuged at 10,000 rpm x 5 min and the cell pellet
resuspended in 100 µL Nucleofector Solution. 2.5 µg plasmid DNA was added to
each reaction. Cell/DNA suspension was transferred to a certified cuvette and
placed in the Nucleofector device for administration of the program U-023 for
normal adult human dermal fibroblasts. Media is immediately added to the
cell/DNA suspension and aliquotted into 4 replicate wells of a 6-well plate. 3
individual transfections were performed for each of 3 plasmid expression vectors.
RNA was extracted at 24 h post transfection and converted to cDNA for qRTPCR quantification of elastin expression.

6.2.5.3 Transfection with Lipofectamine
Human foreskin fibroblasts (ATCC no. SCRC-1041) (HFFs) were plated in
6-well plates at 1.0x104 cells/cm2 overnight prior to transfection. For each well,
2.5 µg DNA (expression vector, and 2.5µL of PLUS reagent was incubated with
100 µL OptiMEM medium for 15 minutes at room temperature. 2.75 µL
Lipofectamine was added to the transfection medium and incubated 30 minutes
at room temperature. One mixture was prepared with 0.5 µg GFP plasmid
following the same procedure; this mixture was used to transfect a separate well
of cells. The plated cells were washed twice with sterile PBS before 2 mL
OptiMEM medium before the DNA containing transfection mixture was added.
Transfection efficiency was assessed at 18 hours by immunofluorescence,
specifically determining the percentage of cells producing GFP in the GFP-
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transfected
extracted,

population.
cDNA

RNA

was

synthesized,

and

mRNA expression levels quantified with
qRT-PCR as described above.

6.2.6 Design of a quantitative Elastin
ELISA
We have taken steps toward
development of a novel in vitro assay

Figure 6.2. 96-well plate setup for
development of a quantitative elastin
assay. The pink circles represent the 60
wells that contained cells while the outer
ring of white circles represent the wells
incubated with PBS in order to prevent
evaporation from cell-containing wells within
the incubator.

that quantifies incorporation of elastin into the ECM of fibroblast monolayers.
Human foreskin fibroblasts (ATCC no. SCRC-1041) were seeded into wells of 96
well culture plates at 1x104 cells/cm2 in media. In order to prevent a ring effect
whereby evaporation occurs from wells on the plate perimeter, the outer wells
are filled with PBS and the inner 60 wells are utilized for the assay as illustrated
in Figure #. Duplicate plates were designed for parallel culture in order to
measure elastin in one plate and normalize to cell viability in a replicate plate.
Pharmacological agents were added in varying concentrations. Control
wells received delivery vehicles. As a control, we administered bacterial
neuraminidase (Neu1) to cultured cells since Neu1 is required for assembly of
elastic fibers (94) and studies have shown administration of Neu1 augments
elastin deposition by VSMCs (50).
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A

B

Figure 6.4. Elastin ELISA quantification is optimal for seeding density after 3 days in
culture. A. Proliferation of human foreskin fibroblasts (HFFS) as measured by MTS assay
reaches a steady state around 3-5 days in culture. B. Elastin deposition by HFFs reaches a
steady state by approximately 4 days in culture. Immunofluorescence of anti-elastin labeling
was detected by elastin ELISA (n=3/timepoint).

Day 3 was chosen as a fixed timepoint because it demonstrates the
transition period between human foreskin fibroblast (HFF) proliferation to steady
state and the point at which the amount of elastin deposition can be assessed
prior to steady state in HFFs (Figure 6.3).
Seeding densities ranging from 102 – 1011 cells/cm2 were assayed by MTS
assay and anti-elastin ELISA. A seeding density of 1 x 104 cells/cm2 was chosen
based on Figure 6.3 where elastogenesis is still occurring in the exponential
A

B

Figure 6.3. Elastin ELISA quantification is optimal for elastin deposition after 3 days in
culture. A. Proliferation of human foreskin fibroblasts (HFFS) as measured by MTS assay
reaches a steady state around 3-5 days in culture. B. Elastin deposition by HFFs reaches a
steady state by approximately 4 days in culture. Immunofluorescence of anti-elastin labeling
was detected by elastin ELISA (n=3/timepoint).
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growth phase but in a large enough quantity to be assayed.

6.2.6.1 Immunostaining Elastin
At 72 hours post treatment, cells were rinsed with PBS and fixed with ice
cold methanol. The monolayer was rinsed 3 times in PBS before incubation in
blocking solution of 5% goat serum in PBS for 30 minutes at room temperature
(RT). Cells were then incubated overnight at 4ºC with 1:1000 primary anti-bovine
elastin antibody (a generous gift from Dr. Mecham) in solution containing 1%
goat serum in PBS. Cells were washed 3 times with PBS before secondary
antibody labeling with 1:10000 horseradish peroxidase (HRP) labeled anti-rabbit
IgG in 1% goat serum in PBS for 45 minutes at RT. All unbound antibody was
washed away with 3 washes of PBS. The cell layer was then incubated with ECL
plus detection reagents containing peroxide to generate chemifluorescence. The
assay was incubated in the dark at RT and chemifluorescence was detected at
15 minute time intervals by spectrophotometry at 430nm. Raw absorbance
values were normalized to cell viability as assessed by MTS assay described
next.

6.2.6.2 MTS Assay for Normalization
Normalization of elastin immunofluorescence was performed using a
colorimetric MTS assay using One Solution Reagent (Promega) to measure cell
viability as a function of metabolic activity. Replicate 96-well plates of HFFs or
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nRASMCs were seeded and cultured identically to conditions set for
immunolabeling.
The One Solution Reagent is comprised of a tetrazolium compound MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt) and an electron coupling reagent PES (phenazine
ethosulfate). PES has enhanced chemical stability, which allows it to be
combined with MTS to form a stable solution. The MTS tetrazolium compound is
reduced by the mitochondria of live cells to yield a formazan product that is
soluble in tissue culture medium. This conversion is presumably accomplished by
NADPH or NADH produced by dehydrogenase enzymes in metabolically active
cells.
At the time of fixation of 96-well plates used in elastin immunolabeling,
One Solution Reagent was added to the parallel plates in order to compare total
viability. 20 µL One Solution Reagent was added via multichannel pipette to each
well of the 96-well plate containing live cells in 100 µL cell culture media and
incubated at 37 ºC in a humidified CO2 incubator. Absorbance was quantified by
spectroscopy at 490 nm at the same 15 minute intervals as parallel plates for
elastin immunolabeling. Background absorbance from control wells containing no
cells was subtracted from the sample absorbance measurements. The MTS
assay has a sensitivity of 800 cells per 96-well plate.
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6.2.7 Fabrication of 3D Gelatin Constructs
6.2.7.1 Cell Culture of Microcarrier Beads
Macroporous gelatin-coated microcarrier beads, CultiSpher-G, (Percell
Biolytica AB, Astorp, Sweden), with an average particle diameter of 130-380 µm,
pore size of 20 µm, and density 1.02-1.04 g/cm3 at 25 ºC, were purchased from
Sigma Chemical Co. (St. Louis, MO). The microcarrier beads were rehydrated,
autoclaved, and preincubated at 37 ºC in cell culture medium according to
manufacturer instructions. Microcarrier beads were combined with HDFs
(passage 4) or HFFs (passage 8) at a ratio of 106 cells per 0.5 mL suspended
microcarrier beads. The cell-microcarrier mixture was added to 50 mL cell culture
medium in a 125 mL siliconized Techne biological stirrer flask (R&D Systems,
Minneapolis, MN). The suspension was subjected to an intermittent stirring
regime (30 min rest, 2 min at 50 rpm) on a Techne Biological Stirrer (model
MCS-104S) for 48 h at 37 ºC in a humidified 5% CO2 incubator. Additional media
(25 mL) was added after 24 h incubation.

6.2.7.2 Tubular Structure Formation in Agarose Molds
An agarose mold for assembling 4 mm tubular structures was created with
2% molten agarose (Low EEO, J.T. Baker Chemical Co., Phillipsburg, NJ) in
Dulbecco’s phosphate buffered saline (PBS) and a template manufactured from
acrylic and polyetheretherketone (PEEK). The template was designed to fit into a
6-well tissue culture plate (Falcon; Becton-Dickinson, Franklin Lakes, NJ)
containing agarose and removed after the agarose had solidified. The agarose
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mold was preincubated with PBS for 1 h and then with cell culture media for 2 h
at 37 ºC in a humidified 5% CO2 incubator. The 48h incubated cell-microcarrier
beads described previously were seeded into the tubular molds and covered with
cell culture media that was replaced every 24h over a culture period of 7 or 14
days at 37 ºC in a in a humidified 5% CO2 incubator.

6.2.7.3 Histological Staining and Immunohistochemistry
For histochemical staining, tubular constructs were dissected away from
the agarose molds and rinsed twice with PBS and fixed in cold methanol for 10
minutes. The structures were rinsed 3 times in PBS before incubation in blocking
solution of 5% goat serum in PBS for 30 minutes at room temperature (RT). Cells
were then incubated overnight at 4ºC with 1:1000 primary anti-bovine elastin
antibody (Dr. Mecham) in solution containing 1% goat serum in PBS. Cells were
washed 3 times with PBS before secondary antibody labeling with Alexa Fluor
546-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat serum in
PBS for 45 minutes at RT. All unbound antibody was washed away with 3
washes of PBS before mounting in Vectashield mounting medium (Vector
Laboratories,

Burlingame,

CA).

Elastin

fibers

were

detected

by

immunofluorescent imaging using a Leica sp5 confocal microscope with a 20X
objective.
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6.3 Results

Table 6.1. Cell associated elastin immunostaining

6.3.1 Elastic Fiber
Assembly
Of

all

the

different cell types
cultured

and

immunolabeled with
the combination of
anti-elastin antibodies, only one cell type displayed extracellular elastic fiber
staining: the human foreskin fibroblast (HFF). Intracellular tropoelastin is seen at
day 3 and by day 5 elastic fibers first appeared in the extracellular matrix space.
The density of fibers increased up to a certain plateau by day 7 and did not seem
to further increase in number or thickness by day 14.
6.3.2 Comparison of Elastic Fiber Assembly by Cell Type
Anti-tropoelastin immunolabeling of certain in vitro cultured cell types
(Table 6.1) produced a diffuse intracellular stain of tropoelastin monomers often

Figure 6.5 Anti-elastin confocal microscopic detection of elastin-containing fibers in
human foreskin fibroblast ECM on successive days of culture. Anti-elastin stained fibers are
green and DAPI stained nuclei are blue.
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appearing punctate. After extended
culture

length

the

tropoelastin

monomers did not appear to migrate
to the extracellular matrix space to
form elastic fibers. It is possible that
in these cell types under these
culture

conditions

assembly is impaired.

elastic

fiber

Figure 6.6. Mithramycin, an antagonist of
Sp1, inhibits elastin expression in a dose
dependent manner in human foreskin
fibroblasts (HFFs). It is known from previous
studies that transcription factor Sp1 enhances
elastogenesis

6.3.3 Screening of Candidate Elastogenic Regulators
The in vitro culture model of HFFs was validated with predicted inhibitor of
elastin transcription, mithramycin A. Increasing concentrations of mithramycin
decrease elastin expression in a dose dependent manner (Figure 6.6).

Figure 6.7. Serum starving HFFs treated with PPARα antagonist decreased elastin
transcription at high concentrations. Reduction in serum levels 24 hours before and
during treatment with PPARα antagonist reversed the previously seen increase in elastin
transcription. Statistical analysis was performed with Student’s T test (p<0.05)
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Figure 6.8. Serum starving HFFs treated with PPARα agonist did not augment elastin
transcription. Reduction in serum levels 24 hours before and during treatment with
PPARα agonist reduced the previously seen increase in elastin transcription. Statistical
analysis with Student’s T test did not validate any regulation of elastin.

Human foreskin fibroblasts (HFFs) cultured in media containing 10% FBS
display seemingly conflicting upregulation of elastin expression in response to
both PPARα agonist and antagonist treatment. Experiments employing serum
starvation with no or low levels of FBS diminished the statistically significant
increase in elastin transcription, however increasing concentrations of PPARα a
gonist

in

0.2%

FBS/DMEM

appeared to trend toward an
increase
Conversely

(Figure
serum

6.8).
starvation

prior to treatment with PPARα
antagonist displayed a reduction
in elastin transcription levels in
0% FBS/DMEM in response to
the highest treatment of 30 µM
PPARα antagonist (Figure 6.7)

Figure 6.9. WT1 antagonist Ganetespib
treatment decreased elastin transcription in a
dose dependent manner in both human foreskin
fibroblasts (HFFs) and rat aortic smooth muscle
cells (RASMCs) as measured by qRT-PCR (n=3
samples/concentration). Statistical analysis
calculated with Student’s T test (p<0.05).
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WT1
antagonist
Ganetespib
treatment
decreased
elastin
transcription in

Figure 6.10. Inhibition of Mek1 with PD98059 does not rescue
downregulation of elastin in response to WT1 antagonist Ganetespib.
Human foreskin fibroblasts (HFFs) and rat aortic smooth muscle cells
were co-cultured with 37nM Ganetespib and 50nM Mek1 inhibitor for 24 h.
Elastin expression was quantified with qRT-PCR and statistical
significance computed with Student’s T test (p<0.05).

a dose dependent manner in both human foreskin fibroblasts (HFFs) and rat
aortic smooth muscle cells (RASMCs) as measured by qRT-PCR (Figure 6.9).
Ganetespib is thus a novel regulator of elastogenesis.
Subsequent experimentation to elucidated the mechanism by which
Ganetespib downregulates elastin employed co-culture of a MEK1 inhibitor
PD98059. The MEK1 inhibitor was unable to rescue downregulation of elastin
transcription in response to WT1 antagonist Ganetespib at the treated
concentration and duration (Figure 6.10).

A

B

Figure 6.11. Neuraminidase (Neu1) does not affect total elastin deposition (A) or rate of
deposition (B) by human foreskin fibroblasts (HFFs) in the elastin assay (n=3/timepoint and
concentration).
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A

B

C

Figure 6.12. Known regulators of elastin were tested in the Elastin ELISA. A, IGF-1 , a
known enhancer of elastogenesis, increased elastin deposition, along with B, pro-gly,
another known enhancer. C, Chondroitin Sulfate (CS), a known inhibitor of elastogenesis,
reduced elastin deposition by HFFs in an elastin ELISA. (n=3/concentration). Statistical
analysis with Student’s T test (p<0.05).

6.3.4 Development toward an ELISA to quantify elastin deposition
Measurement of elastin deposition in response to the Neuraminidase
(Neu1) positive control did not elicit the expected increase in elastin total
deposition or rate of deposition (Figure 6.11). Increasing concentrations of
Neuraminidase did not have any effect on anti-elastin absorbance, neither did
increased culture length. However the proposed negative control Chondroitin
Sulfate (CS), a known inhibitor of elastogenesis, reduced elastin deposition by
HFFs at day 3.
The elastin assay made use of other positive regulator of elastogenesis,
Pro-Gly and IGF-1. Elastin expression was minimally increased with both Pro-Gly
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and IGF-1 treatment, however not in a dose dependent manner (Figure 6.12 A
and B).
A gene from the 63-gene candidate elastogenic set was screened by
exogenous addition of 0.22 – 18 µg/mL Haptoglobin. A significant increase in
elastin was quantified at 2 and 18 µg/mL (Figure 6.13).

Figure 6.13. Haptoglobin increased
elastin deposition by HFFs in an elastin
ELISA (n=3/concentration). Statistical
analysis with Student’s T test (p<0.04).
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6.3.5 Elastin Expression in Transfectants
Expression vector efficiency was
determined with qRT-PCR expression.
WT1 transfected HFFs demonstrated an
85 fold increase in WT1 as compared to
empty vector transfected HFFs. EGR-1
expression was increased approximately
3

fold

6.15).

Figure 6.14 . V3 induced tropoelastin
expression in smooth muscle cells.
PAC-1 cells were transfected with
lipofectamine with V3-containing plasmid
and empty vector control. RNA was
extracted at 24h and expression levels
determined by qRT-PCR with TaqMan
primers for elastin.

(Figure
Statistical

analysis

was

performed with a
Students

T-test

and determined to

Figure 6.15. Transfection of expression vectors validated with
qRT-PCR.

be significant for
WT1

transfected

cells but not for
EGR-1.
Figure
illustrates

6.16
a

dramatic decrease
in

elastin

expression by 89%
(p=0.009)

in

Figure 6.16. Elastin expression is decreased by EGR-1 in HFFs.
Transfected HFFs with plasmid expression vectors was performed
with Lonza Amaxa Nucleofector Kit and qRT-PCR performed on
RNA extracted 24 h post transfection. Elastin expression
significantly decreased by EGR-1 expression by 89%. Elastin
expression is differentially regulated between the WT1 and EGR-1
transfected
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response to a modest, yet not statistically significant, increase in EGR-1
expression. It is possible that expression can be improved with increased number
of transfections thus lowering the standard deviation. Surprisingly only a modest
increase in EGR-1 expression was required for repeated decreases in elastin
expression (n=3). In response to WT1 transfection elastin expression is not
significantly regulated however its mean expression level is 82% higher than
empty vector control. The standard deviation is too large due to large increases
in elastin transcription in only 2 of the 4 transfections. Statistical analysis
between the two experimental groups WT1 transfected HFFs and EGR-1
transfected HFFs is significantly different (p<0.05).
Comparison of multiple transfections points toward a trend in elastin
regulation in response to
WT1.

As

expression
with

WT1
increases

more

efficient

transfections,

the

average expression level
of elastin increases as
measured by qRT-PCR
(Figure 6.17).

Figure 6.17. Elastin expression is trending toward
significance with improved WT1 transfection efficiency.
Comparison of elastin expression in two different transfections
shows a 75% increase in elastin expression (1.08 vs. 1.89) with
a 5.7 fold increase in WT1 (15 vs. 85).
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Figure 6.18. Macroporous gelatin microcarrier beads populated with HFFs. Human
foreskin fibroblasts (HFFs) adhered to gelatin microcarrier beads over 48 hours in a stirred
suspension before seeding into tubular molds. The HFF populated beads fused forming a
tubular structure. Brightfield images were taken at 6 days and 17 days in culture. Remodeling
and filling of the intrabead space either by cells or extracellular matrix is apparent by 17 days.

6.3.6. Elastin Expression in 3D Gelatin Constructs
The beginnings of construction on the proof of concept model of a 3D
gelatin construct from macroporous gelatin-coated microcarrier beads and
human foreskin fibroblasts (HFFs) were generated. Fusion of the beads occurred
after 7 day of culture in the tubular shaped molds and strengthened in tension as
noticed by handling with increasing culture duration. Cellular staining indicated
infiltration of some cells into the pores but the majority of HFFs were attached to
the bead surface or in the extracellular space between beads. Anti-elastin
staining demonstrated the presence of mature elastic fibers at 7 days and 12
days in culture (Figure 6.19).
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Figure 6.19. Elastin immunostaining of macroporous gelatin microcarrier beads
populated with HFFs. Human foreskin fibroblasts (HFFs) adhered to gelatin microcarrier
beads over 48 hours in a stirred suspension before seeding into tubular molds. The HFF
populated beads fused forming a tubular structure and were fixed at day 7 and day 12 and
immunostained for elastin.

6.4 Discussion
Increasing concentrations of mithramycin, an antagonist Sp1, a known
augmenter of elastogenesis in HFFs decreased elastin expression, thus
validating the tissue culture model as an appropriate assay for regulators of
elastin transcription.
WT1 antagonist Ganetespib treatment decreased elastin transcription in a
dose dependent manner in both human foreskin fibroblasts (HFFs) and rat aortic
smooth muscle cells (RASMCs) as measured by qRT-PCR. This marks the first
time a WT1 antagonist has been shown to downregulate elastin transcription.
Subsequent experimentation aimed at elucidating the mechanism by
which Ganetespib downregulated elastin targeted the MAPK pathway. Co-culture
of a MEK1 inhibitor PD98059 attempted to disrupt downstream signaling of Egr1, a hypothesized suppressor of elastogenesis. The MEK1 inhibitor was unable
to rescue downregulation of elastin transcription in response to WT1 antagonist
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Ganetespib at the treated concentration and duration. It is possible that the
MEK1 inhibitor did not fully disrupt downstream signaling as it did not block
MEK2. Future studies could aim to target MEK1/2 or the downstream target of
ERK 1/2 to decrease Egr-1 signaling. It is also possible that the concentration of
MEK1 inhibitor at 50 nM was too low to fully suppress all MEK1 signaling. A
concentration increase of MEK inhibitor can be performed to possibly generate
an increase in elastin transcription.
Contrary to expected results, elastin expression increased in HFFs treated
with both PPARα agonist and PPARα antagonist. If only PPARα levels are
changing in response to the agonist and antagonist, then it would follow that any
effects seen would have opposing expressions. It is likely that the PPARα
agonist or PPARα antagonist is inducing transcription via stimulation of another
enhancer of elastin transcription. Follow-up qRT-PCR was performed on
expression levels of PPAR∂. In smooth muscle cells, PPAR∂ agonist was shown
to increase tropoelastin production (274). qRT-PCR confirmed that PPARα
antagonist increased PPAR∂ expression, possibly as a compensatory response
to decreased PPARα activity. Future experimentation should neutralize the
increase in PPAR∂ by incorporation of the appropriate concentration of PPAR∂
antagonist.
Steps toward the development of an elastin ELISA based on anti-elastin
labeling normalized to MTS assay of cellular proliferation were taken to quantify
total elastin deposition and rate of deposition. An optimal timepoint of
quantification was established at three days of culture while elastin deposition
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and cell proliferation are still in the exponential growth phase prior to steady
state. Optimal seeding density of A seeding density of 1 x 104 cells/cm2 was
chosen at which point elastin is being deposited in the exponential growth phase
at a large enough quantity to be assayed.
Contrary to expected results, Neu1, a positive regulator of elastogenesis
did not increase total elastin deposition or rate of deposition as measured by
elastin ELISA. Other positive regulators Pro-Gly and IGF-1 did show a marginal
increase in elastin deposition with statistical significance assessed by Students T
test, however not in a dose dependent manner as expected. Chondroitin Sulfate,
a negative regulator of elastogenesis also passed the Student’s T test of
significant regulation but the decrease in elastin deposition did not occur at
intermediate timepoints.
The conflicting or marginal results could be due to the need for increased
optimization of the parameters surrounding the elastin ELISA. Subsequent
analyses could be performed to alter cellular seeding density, length of culture,
and media concentration of FBS. If elastin expression is quantifiable in an in vitro
system but elastin deposition is not as easily quantified, It is also possible that
oxidative and nitrosative modification of tropoelastin within the in vitro model are
preventing elastic fiber assembly (28). In a study by Akhtar et al. oxidation
reduced crosslinking and interactions with other proteins required for elastic fiber
assembly,

including

fibulin-4,

fibulin-5,

and

fibrillin-2.

Measurement

of

exogenously added oxidized tropoelastin showed less incorporation into the
preexisting microfibrils of human retinal pigmented epithelial ARPE-19 cells
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compared to unoxidized tropoelastin as detected by immunofluorescence
microscopy (28). Nitration of TE was confirmed using the rabbit anti-N-Tyr
antibody, followed by a FITC-conjugated anti-rabbit secondary antibody (28). If
the in vitro culture model for the elastin ELISA is undergoing any oxidative stress,
it would follow that elastic fiber assembly may be impaired. Gene ontological
analysis of the 63 candidate elastogenic genes shows enrichment for the
functional group of oxidoreductase which facilitates redox reactions. It is also
possible that oxidative and nitrosative modification of tropoelastin within the in
vitro model are preventing elastic fiber assembly (28). In a study by Akhtar et al.
oxidation reduced crosslinking and interactions with other proteins required for
elastic fiber assembly, including fibulin-4, fibulin-5, and fibrillin-2. Measurement of
exogenously added oxidized tropoelastin showed less incorporation into the
preexisting microfibrils of human retinal pigmented epithelial ARPE-19 cells
compared to unoxidized tropoelastin as detected by immunofluorescence
microscopy (28). Nitration of TE was confirmed using the rabbit anti-N-Tyr
antibody, followed by a FITC-conjugated anti-rabbit secondary antibody (28). If
the in vitro culture model for the elastin ELISA is undergoing any oxidative stress,
it would follow that elastic fiber assembly may be impaired.
An optional culture model to pursue for screening of elastogenic regulators
is the 3D culture of macroporous gelatin microcarrier beads seeding with human
foreskin fibroblasts (HFFs). Deposition of elastic fibers is seen at 12 days in
culture but not at 7 with an increase in culture duration also correlating with an
increased ease in handling. The rings remained solid after 12 days and did not
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dissociate into fragments. The 3D model offers advantages to 2D culture models
by mimicking the increase in cell-cell contact and cell-scaffold contact in the
native ECM environment, thus more closely evoking native cell responses.
Overall 3D, ECM-based cell scaffolds are superior over 3D synthetic scaffolds or
two dimensional (2D) monolayer cell cultures in efforts to simulate the chemical
and physical environment of tissues (86, 88). This model can serve to screen
potential regulatory gene and transcription factors in future studies.

6.5 Conclusion
Increasing concentrations of mithramycin, an antagonist Sp1, a known
augmenter of elastogenesis in HFFs decreased elastin expression, thus
validating the tissue culture model as an appropriate assay for regulators of
elastin transcription. While elastin transcription can be appropriately assessed,
steps toward development of an elastin ELISA displayed conflicting or marginal
variance of elastin deposition between experimental and control wells. Further
optimization of the assay is required in order to clearly distinguish the effects of
elastogenic regulators.
Screening of transcription factors identified as potential regulators of
elastogenesis by PAINT with pharmacological agents discovered a novel
regulator of elastin transcription. Ganetespib, a WT1 antagonist, repeatedly
downregulates elastin expression in a dose dependent manner. The mechanism
by which Ganetespib mediates elastin downregulation has yet to be determined,
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however it wasn’t altered with co-culture of 50 nM MEK1 inhibitor aimed at
disrupting downstream regulation of EGR-1 via the MAPK pathway.
Egr-1, a member of the same transcription factor family as WT1, binds the
same transcriptional regulatory elements (TREs) and is known to regulate the
same genes, often in opposing directions whereby EGR1 activates the
transcription of genes that WT1 represses (257, 258). Expression of Egr-1 by
transfection of plasmid expression vectors results in decreased elastin
transcription. This result fits the story of opposing roles of WT1 and Egr-1 for
regulation of elastin transcription. Experimentation to augment elastin expression
by expression of WT1 plasmid expression vector is trending toward an increase
in elastin expression, however it has not approached statistical significance.
Incorporation of additional transfections to increase statistical power may
overcome standard deviation to yield an increase in elastin.
Future studies can also employ the use of an elastin producing 3D culture
model incorporating human foreskin fibroblasts (HFFs) with gelatin microcarrier
beads. Tubular constructs were created and after 12 days of culture were
manageable and populated with mature elastic fibers. This proof of concept
culture system provides the advantages of more closely mimicking the native cell
environment in a 3D environment as compared to a 2D monolayer culture.
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CHAPTER SEVEN
CONCLUSIONS, STUDY LIMITATIONS, AND FUTURE DIRECTIONS
7.1 Conclusions
Particularly important to the mechanical performance of tissues is elastin,
an extracellular matrix (ECM) protein deposited by vascular smooth muscle cells
(VSMCs) in the form of elastic fibers. In addition to serving as major structural
elements of tissues, providing extensibility and elastic recoil, elastic fibers also
influence vascular cell behaviors such as biochemical signaling pathways.
Disruption of elastic fibers can initiate and progressively lead to the pathology of
life

threatening

complications

such

as

atherosclerosis,

aneurysm

and

vasospasms (4, 5). Failure to regenerate a healthy elastin matrix in response to
damage during disease (e.g., inflammation-mediated elastin degradation in
atherosclerosis) can severely compromise elastic tissue homeostasis (13, 14). A
major concern in the construction of tissue engineered elastin-rich tissue is the
ability to regulate cell behavior and encourage the regeneration of elastin fibers.
The overarching goal of this application was to advance an approach to
regenerative medicine involving accelerated production of elastic fibers. Severe
quantitative and qualitative deficiencies in the process of elastogenesis exhibited
by cultured cells (28, 29) create an impediment to the engineering of tissues
requiring functional elastin architecture.
Through convergent DNA microarray analysis of gene expression profiles
associated with normal elastogenesis occurring during 1) mouse lung and aorta
development, 2) elastogenesis in lung and skin in response to injury, and 3) in
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vascular smooth muscle cells (VSMCs) stimulated to produce elastin fibers, 63
commonly regulated genes were identified genes with known regulators of elastin
formation (Eln, Lox, Mfap2, Mfap5) and genes that appear to represent new
players in the process of elastogenesis.
Gene ontological analysis highlighted functional categories of extracellular
matrix (ECM) and secretion, which follow the elastin gene beginning with
secretion of a tropoelastin monomer and subsequent assimilation into mature
elastic fibers comprising the ECM. The enrichment for the ontological group of
oxidoreductase enzymes may prove to be a hindrance to elastogenesis as
oxidation of tropoelastin prevents proper elastic fiber assembly. This may pertain
primarily to the elastogenic processes of wound healing that are undergoing
oxidative stress and ultimate assembly of inferior elastic fibers compared to
developmental elastic fibers. Hierarchical organization of gene regulation within
the 5 different elastogenic processes yielded a table of genes ranging from most
similarly expressed as elastin to down to most differentially regulated compared
to elastin (Appendix A). Group V highlights genes regulated similar to elastin
during injury and different from elastin during development. These genes may
provide insight into inferior elastic fiber quality in injury models.
Promoter Analysis and Interaction Network Generation Tool, PAINT,
predicted the likelihood of transcription factor binding subset of the 63-gene
candidate elastogenic set in which expression patterns were similar to elastin
characterized 11 overrepresented TREs of which four were previously known to
regulate elastogenesis: B-Myb Sp1, cKrox and PPAR. A closer look at the TREs
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enriched within the elastin promoter revealed five overrepresented TREs, of
which two were known form previous studies to regulate elastin: PPAR and Sp1.
The finding of elastogenic transcription factors validates the use of PAINT to
identify regulators of elastogenesis. Many new candidate elastin regulating
transcription factors were identified for which pharmacological agents exist and
can ultimately be tested for effects on elastogenesis.
Specific mapping of TREs using chromatin immunoprecipitation (ChIP)
studies and the UCSC Genome Browser illustrated binding sites for PPAR, a
PPAR coactivator, and WT1/EGR-1 around the elastin transcription start site.
The likelihood of TF/TRE binding in the elastin promoter indicates PPAR and
WT1/EGR-1 as potential regulators of elastogenesis.
Additional gene regulation was assessed through target mRNA searches
with microRNA.org. MicroRNA (miRNA) binding sites on the 63 genes in the
candidate elastogenic gene set were particularly prevalent in Lox, an important
crosslinker of elastin fibers. Additionally miR-29, a known regulator of
elastogenesis, was significantly predominant within the 63-gene elastogenic
gene set. It is likely that other miRNAs highlighted in the miRNA analysis play a
likely role in the regulation of elastogenesis.
Increasing concentrations of mithramycin, an antagonist Sp1, a known
augmenter of elastogenesis in HFFs decreased elastin expression, thus
validating the tissue culture model as an appropriate assay for regulators of
elastin transcription. While elastin transcription can be appropriately assessed,
steps toward development of an elastin ELISA displayed conflicting or marginal
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variance of elastin deposition between experimental and control wells. Further
optimization of the assay is required in order to clearly distinguish the effects of
elastogenic regulators.
Screening of transcription factors identified as potential regulators of
elastogenesis by PAINT with pharmacological agents discovered a novel
regulator of elastin transcription. Ganetespib, a WT1 antagonist, repeatedly
downregulates elastin expression in a dose dependent manner. The mechanism
by which Ganetespib mediates elastin downregulation has yet to be determined,
however it wasn’t altered with co-culture of 50 nM MEK1 inhibitor aimed at
disrupting downstream regulation of EGR-1 via the MAPK pathway.
Egr-1, a member of the same transcription factor family as WT1, binds the
same transcriptional regulatory elements (TREs) and is known to regulate the
same genes, often in opposing directions whereby EGR1 activates the
transcription of genes that WT1 represses (257, 258). Expression of Egr-1 by
transfection of plasmid expression vectors results in decreased elastin
transcription. This result fits the story of opposing roles of WT1 and Egr-1 for
regulation of elastin transcription. Experimentation to augment elastin expression
by expression of WT1 plasmid expression vector is trending toward an increase
in elastin expression, however it has not approached statistical significance.
Incorporation of additional transfections to increase statistical power may
overcome standard deviation to yield an increase in elastin.
Future studies can also employ the use of an elastin producing 3D culture
model incorporating human foreskin fibroblasts (HFFs) with gelatin microcarrier
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beads. Tubular constructs were created and after 12 days of culture were
manageable and populated with mature elastic fibers. This proof of concept
culture system provides the advantages of more closely mimicking the native cell
environment in a 3D environment as compared to a 2D monolayer culture.

7.2 Study Limitations
7.2.1 Microarray Limitations
Elastin is highly expressed in utero and then strongly downregulated after
birth (275, 276). Only low maintenance levels of tropoelastin mRNA are found in
most elastic tissues in adults (276, 277). Repair of severe injuries, such as thirddegree burns, produces tissue that is often heavily scarred and severely limited
in flexibility, range of motion, and tissue function (278). Similar scarring is seen
after prolonged cancer radiation therapy, in sun-damaged skin (279), and in
systemic sclerosis (280, 281), In the vasculature, Eln haploinsufficient
phenotypes include narrowing (stenosis) of the ascending aorta in the perinatal
period and hypertension later in life. Production of a collagen-rich extracellular
matrix (ECM) that is deficient in elastic fibers occurs following these injury
induced conditions. A major cause of the deficiency in elastic fiber production is
the failure to upregulate tropoelastin gene expression in postnatal tissues. It is a
recognized risk that in models of elastogenesis not occurring during development
in which lower quality or defective elastic fibers are produced, comparison of
commonly regulated genes may exclude certain critical genes. It is however
necessary to include processes in which elastogenesis occurs outside of
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development so as to preen the convergent list of regulated genes from
commonly regulated genes specific to development. Comparison of the genes
common to developmental processes of elastogenesis to injury models or in vitro
models could shed light on key genes responsible for elastic fiber defects in
wound repair and in vitro.

7.2.2 Epigenetic Regulation
In addition to studying gene expression, transcription factor induction of
gene expression and microRNA inhibition of gene expression, newer findings
suggest the importance of regulation at the epigenetic level. Epigenetic
regulation refers to heritable changes in gene regulation that occur without a
change in the DNA sequence and are therefore not encoded at the genomic level
and can therefore not be assessed by microarray technology. Epigenetic
regulation primarily concerns the chromatin structure and the possible chemical
modification of some DNA bases.
DNA molecules are tightly wound around proteins known as histones to
form a complex known as chromatin. Post-translational modification of histones
alters their interaction with DNA and with proteins in the cell's nucleus.
Combinations of such modifications are thought to constitute a code, the socalled “histone code” that plays a role in genome function, including gene
regulation and DNA repair. Additionally DNA can be modified mainly by DNA
methylation, typically occurring at CpG sites, that is, at sites where a cytosine (C)
is directly followed by a guanine (G) in the DNA sequence. Such sites are often
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found at higher density near gene promoter sequences where they are
collectively referred to as CpG islands. Both chromatin structure and CpG islands
have become an increasing concern of computational biologists although good
models and data are often missing to be able to conduct large-scale exploratory
computer studies.
7.2.3. 2D culture model
In summary I have shown HFFs are very efficient producing elastin fibers
after 3 days in culture as compared to other cell types which did not produce any
extracellular fibers (PAC-1, HDF, HASMC, RASMC, MLF). Also relative amounts
of elastin mRNA are higher in HFFs compared to other cells (PAC-1, HDF,
HASMC). These findings indicate that HFFs are efficient at in vitro elastin
formation. Because of the known opposing regulatory roles of transcription
factors WT1 and Egr-1 along with experimental findings of a decrease in elastin
transcription in both HFFs treated with a WT1 antagonist and also HFFs
transfected to express EGR-1, it would follow that elastin transcription would be
upregulated in response to WT1 expression. Because repeated experiments
have yet to yield significantly upregulated elastin transcription it may not be
possible in this 2D culture system of HFFs to see a substantial increase in elastin
transcription. It is possible that HFFs are assembling elastic fibers at maximum
capacity with no possible cellular resources for augmentation of transcription.
It has been shown that 3D, ECM-based cellular scaffolds offer overall
superiority over 3D synthetic scaffolds and 2D monolayer cell cultures in in
efforts to simulate the chemical and physical environment of tissues (86, 88). 3D
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culture models most closely mimic native cell environment whereby cells within
3D scaffolds come into contact with other cells and ECM in three dimensions and
are therefore expected to more closely evoke native cell responses than 2D
substrates.

7.3 Future Directions
7.3.1 Modulation of Differentially Expressed Genes in Development vs. Injury
Hierarchical organization of gene regulation within the 5 different
elastogenic processes yielded a table of genes ranging from most similarly
expressed as elastin to down to most differentially regulated compared to elastin
(Appendix A). Group V highlights genes regulated similar to elastin during injury
and different from elastin during development. These genes may provide insight
into inferior elastic fiber quality in injury models. Inhibition of this set of genes
may suppress inherent inhibitors or adult elastin expression, inflammation
associated genes, or oxidative stress resulting in an upregulation of
elastogenesis quantity and quality.
Wound healing models incorporating an injury such as naphthalene
injection or skin punch biopsy and subsequent elastin regeneration as described
in the convergent microarray analysis would provide an excellent model for
testing this group of genes. In vitro culture models of wound healing can also be
evaluated such as a scratch test assay. A confluent monolayer of elastin
producing cells (e.g., HFFs, nRASMCs) is first cultured with sufficient time to
deposit a rich extracellular matrix (~7 days). The monolayer is then disrupted and
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a group of cells destroyed or displaced by scratching a line through the layer.
The open gap is then slowly closed during “healing” by migrating cells to cover
the damaged area. Addition of pharmacological antagonists to Aebp1, Cebpa,
Cebpb, Hk2, Por, or Ptgis can be added in experimental groups. Some
antagonists may need to be added under serum starved conditions to increase
effectiveness. Cell layers can be fixed at 2, 3, 4, and 5 days post injury for
immunostaining of elastin to assess elastic fiber quality. Cell monolayers can be
rinsed twice with PBS and fixed in cold methanol for 10 minutes. The monolayers
can be rinsed 3 times in PBS before incubation in blocking solution of 5% goat
serum in PBS for 30 minutes at room temperature (RT). Cells can then incubate
overnight at 4ºC with 1:1000 primary anti-bovine elastin antibody (Dr. Mecham) in
solution containing 1% goat serum in PBS. Cells can then be washed 3 times
with PBS before secondary antibody labeling with Alexa Fluor 546-conjugated
anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat serum in PBS for 45
minutes at RT. All unbound antibody will be washed away with 3 washes of PBS
before mounting in Vectashield mounting medium (Vector Laboratories,
Burlingame, CA). Elastin fibers can be detected by immunofluorescent imaging
using a Leica sp5 confocal microscope.
An alternate in vitro wound healing model could incorporate Electronic
Cell-substrate Impedance Sensing (ECIS) plates. A monolayer of cells could be
cultured as before and injured via high voltage shocks. This model has the
advantage of reducing injury variability. Immunostaining can be performed as
described previously.
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RNA can be extracted and qRT-PCR performed as described previously. This
model also offers the increased data collection capabilities of impedance as cells
migrate to cover the gap during the wound healing process. Antagonism to the
genes identified as upregulated in wound healing of elastogenesis and
downregulated during developmental elastogenesis may lead to increased elastic
fiber quality, larger diameter or length of continuous fibers, or increased rate to
elastic fiber deposition.

7.3.2 MicroRNA Studies
miRNAs inhibition may prove to enhance elastin transcription. miR-23 is
known to restrict cardiac valve formation by inhibiting hyaluronic acid synthase 2
(Has2) and production of extracellular hyaluronic acid (HA) (282). HA facilitates
the synthesis and organization of microfibrils (fibrillin), a microfibrillar scaffold
component for elastic fiber deposition (283). HA has been suggested to play an
indirect role in elastogenesis through its intimate binding of versican (65) which in
turn interacts with microfibrillar proteins (fibulin-1, 2) and elastin-associated
proteins to form higher-order macromolecular structures important for elastic fiber
assembly (65, 284-286). The highly anionic nature of HA causes soluble
tropoelastin to assemble and facilitates LOX-mediated crosslinking into an
insoluble matrix (287, 288), and stabilize elastin fibers against degradation by
elastase (286, 289, 290). Inhibition of miR-23 may increases HAS2 and HA and
subsequent elastin may be upregulated.
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Alternate miRNAs to target in future studies are miR-133 and miR-590. In
a study by Shan et al. nicotine produced significant upregulation of expression of
TGF-β1 and TGF-βRII at the protein level, and a 60–70% decrease in the levels
of miRNAs miR-133 and miR-590 (291). TGF-β1 and TGF-βRII are targets for
miR-133 and miR-590 repression so the downregulation of miR-133 and miR-590
partly accounts for the upregulation of TGF-β1 and TGF-βRII. Additionally,
transfection of miR-133 or miR-590 into cultured atrial fibroblasts decreased
TGF-β1 and TGF-βRII levels and collagen content (291). Canonical TGFβ
signaling has been shown to upregulate elastin in fibroblasts (118, 122) and
aortic cells (120). Inhibition of miR-133 and miR-590 with anti-sense miRNAs
may increase levels of TGF-β1 and TGF-βRII and stimulate tropoelastin
expression.
Experimentation to assess the effects of miR-23, miR-133, or miR-590 on
elastogenesis can incorporate antisense oligonucleotides (ASOs) or anti-miRNA
oligonucleotides (AMOs) to selectively bind target miRNAs or their mRNA
targets. AMOs are synthetic nucleotides that can be transfected into the cell to
inhibit miRNA activity. Human foreskin fibroblasts can be plated in 6-well plates
at 1.0x104 cells/cm2 overnight prior to transfection. For each well, 2.5 µg DNA
(expression vector, and 2.5µL of PLUS reagent can be incubated with 100 µL
OptiMEM medium for 15 minutes at room temperature. 2.75 µL Lipofectamine
can be added to the transfection medium and incubated 30 minutes at room
temperature. One mixture can be prepared with 0.5 µg GFP plasmid following the
same procedure; this mixture can be used to transfect a separate well of cells.

151

The plated cells will need to be washed twice with sterile PBS before 2 mL
OptiMEM medium before the DNA containing transfection mixture was added.
Transfection efficiency can be assessed at 18 hours by immunofluorescence,
specifically determining the percentage of cells producing GFP in the GFPtransfected population.
RNA can then be extracted at 12 h, 24 h, 48 h, and 72 h post injury and
converted to cDNA. Elastin transcription can be assessed by qRT-PCR of elastin
normalized to a reference gene (B2M) as described in Chapter 4.2.

7.3.3 PPAR delta Regulation
QRT-PCR confirmed that PPARα antagonist increased PPAR∂ expression
in HFFs, possibly as a compensatory response to decreased PPARα activity.
The next experimentation should attempt to neutralize PPARα-mediated
upregulation of PPAR∂ and subsequent upregulation on elastin expression.
PPAR∂ can be eliminated from the PPARα experimentation as an independent
variable by determining the appropriate concentration of PPAR∂ antagonist to
add to all experimental samples and control.
Preliminary studies assessed the effects of varying concentrations of
PPAR∂ antagonist on HFFS (1.11, 3.33, 10 and 30 µM) with no significant effects
on elastin expression (Figure 7.1). The next step in experimentation should be to
coculture PPARα antagonist with varying concentrations of PPAR∂.

152

HFFs can be plated at confluence and allowed to attach overnight before
treatment with 1.11 – 10 µM PPARα antagonist (GW6471, Sigma), and/or 1.11 10 µM PPAR∂ antagonist.
Different PPAR∂ antagonists
can

be

tested

as

well.

GSK0660 is a potent PPARβ/δ
antagonist with a pIC50 of 6.8
(160 nM). GSK0660 is nearly
Figure 7.1. HFFs treated with PPAR∂ did not effect
elastin expression. HFFs were cultured with 1.11,
3.33, 10, and 30 µM PPAR∂ antagonist (4
samples/concentration).

inactive on PPARα and PPARγ
with IC50s greater than 10 µM.
Another PPAR∂ antagonist,

PT-S58, is a PPAR β/δ full antagonist, and a derivative of GSK0660. PT-S58 has
a three-fold higher affinity for the receptor than GSK0660 and is a potent inhibitor
of agonist-induced target gene expression. Unlike GSK0660, PT-S58 blocks the
recruitment co-repressor molecules such as SMRT.
Because the antagonists inhibit PPAR∂ activity, QRT-PCR cannot be used
to validate inhibition by PPAR∂ expression. PPAR∂ activity can be measured by
immunoblotting. Cell lysates can be fractionated into cytosolic and nuclear
fractions, and proteins separated by SDS-PAGE, transferred to polyvinylidene
difluoride membranes and immunoblotted with specific antibodies as described
by . Protein levels can then be determined by densitometry and PPAR∂
antagonist concentration can be optimized to reduce PPAR∂ levels to the same
as control treated samples.
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Experimentation can then be performed with coculture of PPARα
antagonist and PPAR∂ antagonist for 24 h, 48 h, and 72 h prior to RNA extraction
using Qiagen’s RNeasy RNA extraction kit according to the manufacturer’s
instructions. RNA integrity can be tested by Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA) and cDNA can be prepared using the iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA) with 1 µg RNA according to the
manufacturer’s instructions. cDNA preparations can be diluted 1:10, and 3 µL
used in 10-µl reactions for qRT-PCR as described previously in 6.2.3 to assess
elastin expression levels. It is expected that PPAR∂ antagonist treatment will
reduce PPAR∂ levels back to baseline levels when cocultured with PPARα
antagonist and elastin expression levels will be decreased.

7.3.4 Elucidation of the Mechanism by which Ganetespib Decreases Elastin
Expression
Future studies could aim to target MEK1/2 or the downstream target of
ERK 1/2 to decrease Egr-1 signaling. It is also possible that the concentration of
MEK 1 inhibitor at 50 nM was too low to fully suppress all MEK 1 signaling. A
concentration increase of MEK inhibitor PD98059 can be performed in a 3-fold
dose dependent manner at 50 nM, 150 nM, 450 nM, and 1.35 µM PD98059.
Increased concentration is expected to fully inhibit Mek1 and generate an
increase in elastin transcription. An alternate inhibitor, U0126, displayed a higher
affinity for MEK 1 and also inhibits MEK 2. Treatment of HFFs with variable
concentrations of U0126 may be a more potent inhibitor of the MAPK pathway
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and potential downstream EGR-1 signaling. Experiments can aim to reverse the
downregulatory effects of Ganetespib on elastin expression through coculture of
Ganetespib and U0126. RNA can be extracted at 12 h, 24 h, and 36 h post
treatment and elastin expression can be quantified by qRT-PCR for elastin.
Alternately these experiments can be conducted under serum-free
conditions along with serum starvation pre-treatment with antagonists in order to
increase potency of antagonists.

7.3.5 Candidate Regulator Screening in 3D HFF-Gelatin Microcarriers Culture
Model
The proof of concept of construction of a 3D tubular structure offers
advantages to 2D culture models by mimicking the increase in cell-cell contact
and cell-scaffold contact in the native ECM environment, thus more closely
evoking native cell responses. An optional culture model to pursue for screening
of elastogenic regulators is the 3D culture of macroporous gelatin microcarrier
beads seeding with human foreskin fibroblasts (HFFs). Deposition of elastic
fibers is seen at 12 days in culture but not at 7 with an increase in culture
duration also correlating with an increased ease in handling. The rings remained
solid after 12 days and did not dissociate into fragments.
Experimentation aimed to test candidate regulatory genes, transcription
factors, and miRNAs can utilize the 3D culture model to hopefully obtain more
substantial effects on elastin deposition and/or rate to elastin deposition.
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Following the same protocol for HFF seeding of gelatin microcarrier beads as
described in 6.2.7. Experimental agonists, antagonists, or antisense-miRNAs can
be added exogenously in the media after plating the HFF-bead complexes into a
tubular structure. After 5 d, 7 d, and 9 d of treatment, the tubular structures can
be fixed in ice cold methanol and labeled with anti-elastin antibodies as
described in 6.2.7.
It is expected that potential enhancers of elastogenesis may increase the
rate of elastin deposition, therefore those tubular structures can be fixed for antielastin immunohistochemistry earlier than control rings are expected to display
intact elastic fibers. Potential inhibitors can be fixed at later timepoints to address
whether an inhibitor may act to decrease overall elastin deposition or decrease
rate to elastic fiber formation. Total elastin deposition can be semi-quantitated
with densitometry of immunoflurorescent images. Additional measurements of
elastic fiber diameter and length can be used to address overall elastic fiber
quality. A truly quantitative measurement of total elastin deposition can be
determined with immunoblotting. Elastin protein can be isolated and purified as
described by Dr. Mecham (265)wt1.
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APPENDICES
Appendix A
A. Hierarchical Table of 63 Regulated Genes in Convergent Microarray Analysis
of Processes in which Elastogenesis is a Key Component
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Table A: Convergent microarray analysis of processes in which elastogenesis is
a key component identified 63 genes as potential regulators of elastogenesis
which are depicted in a hierarchal Table A-2 from genes whose expression
pattern is most similar to elastin descending to genes whose expression pattern
is most different from elastin across all 5 processes. An “X” in the table is
representative of having met the criteria in Table A-1.
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Appendix B
Figure B: Heatmaps of Significantly Regulated Genes in Response to Versican
V3 Expression in Vascular Smooth Muscle Cells (VSMCs)
A

B

Figure B-1: The 3 sample pair analysis of yielded 521 genes significantly
regulated in response to V3 with a fold change > 1.5 and a paired Student’s Ttest p<0.05. The false discovery rate (FDR) is 1.7%. Increasing the fold change
to 2.0 decreases the number of significant genes to 247 with an FDR of 0.0%.
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Appendix C
Figure C: Versican effects on TGFβ Signaling

Figure C: The 3 sample pair analysis yielded 8 significantly regulated genes in
the TGFβ pathway. Increases of expression are seen in ROCK1 and TGFβ3
while decreases in the expression of Decorin, Comp, Bmp6, TGFβ1, Fst, and
InhbB.
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Appendix D
Figure D. Human Elastin Splice Variants

Figure D. The human elastin gene mRNA is alternately spliced into 5 different
variants. Elastogenic cells produce multiple forms of tropoelastin mRNA within
the same tissue, suggesting there may not be a functional or architectural
difference between isoforms (292). The isoforms vary in size from 692 – 724
translated amino acid residues. The exons code for either hydrophobic (Variable)
segments or lysine-rich crosslinkable (conserved) segments of elastin.
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